MXPA00012308A - Imidazolyl derivatives - Google Patents

Abstract

The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors.

Description

DERIVATIVES OF IMIDAZOLILO BACKGROUND OF THE INVENTION The present invention is directed to compounds and e. compositions containing compounds that selectively bind somatostatin receptor subtypes and the use of these compounds to treat medical disorders mediated by somatostatin receptor subtypes. Somatostatin (somatotropin release inhibiting factor, SRIF), a tetradecapeptide hormone, originally isolated from the bovine hypothalamus (Brazeau, P. et al., Science 179, 77-79, 1973) has been shown to have a wide range of regulatory effects on the release of a variety of hormones such as growth hormone, prolactin, glucagon, insulin, gastrin (Bloom, SR and Poldack, JM Brit. Med. J. 295, 288-289, 1987). In addition, antiproliferative properties (Reichlin, S., N. Engl. J. Med. 309, 1495-1501, 1983) have been obtained with somatostatin analogs in metastatic prostatic cancer (Parmar, H. et. Al., Clin. Exp. Metastasis, 10, 3-11, 1992) and in several other neuroendrocrine neoplasms in man (Anthony, L. et al., Acta Oncol., 32, 217-223, 1993). The metabolism of somatostatin by aminopeptidases and carboxypeptidases leads to a short duration of action. The actions of somatostatin were measured via membrane-bound receptors. The heterogeneity of its biological functions has led to studies to identify structure-activity relationships of peptide analogs in somatostatin receptors that resulted in the discovery of five receptor subtypes (Yamada, et al., Proc. Nati. Acad. Sci. USA 89, 251-255, 1992, Raynor, K. et al., Mol.Pharmacol., 44, 385-392, 1993). The functional roles of these receptors are under extensive investigation. The binding to different types of somatostatin subtypes has been associated with the treatment of the following conditions and / or diseases. The activation of types 2 and 5 has been associated with the suppression of growth hormone and more particularly, with adenomas that secrete GH (Acromegaly) and adenomas that secrete TSH. Activation of type 2, but not type 5, has been associated with the treatment of adenomas secreting prolactin. Other indications associated with the activation of the somatostatin subtypes are restenosis, insulin and / or glucagon inhibition and more particularly diabetes mellitus, hyperlipidemia, insulin insensitivity, syndrome X, angiopathy, proliferative retinopathy, onset and nephropathy; inhibition of gastric acid secretion and, more particularly, peptic ulcers, enterocutaneous and pancreatic fistula, irritable bowel syndrome, emptying syndrome, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis and tumors that secrete gastrointestinal hormone; cancer treatment such as hepatoma; inhibition of angiogenesis; treatment of inflammatory disorders such as arthritis; chronic allograft rejection; angioplasty; prevention of gastrointestinal bleeding and grafted spleen. Somatostatin agonists can also be used to decrease the body weight in a patient. In drug research, it is a key issue to minimize side effects by developing highly potent and selective drug molecules. Recent work in the development of non-peptidic structures (Hirschmann, R. et al., J. Am. Che. Soc. 115, 12550-12568, 1993; Papageorgiou, C. and Borer, X., Bioorg. Med. Chem. Lett 6, 267-272, 1996) has described compounds with low affinity to the somatostatin receptor. The present invention is directed to a family of non-peptide compounds, which are selective and potent ligands to the somatostatin receptor.

SUMMARY OF THE INVENTION In one aspect, the present invention is directed to a compound of Formula (I), Or the racemic-diastereomeric mixtures and optical isomers of the compounds of the Formula (I), the pharmaceutically acceptable salts and prodrugs thereof or a pharmaceutically acceptable salt thereof, wherein represents an optional bond; R1 is H, - (CH2) m-C (0) - - (CH2) m -Z, - (CH2) m-0-Z1 or - (C0-C6) alkyl-C (O) -NH- (CH2) m-Z3, Z1 is an optionally substituted portion selected from the group consisting of alkyl of 1 to 12 carbon atoms, benzo [b] thiophene, phenyl , naphthyl, benzo [b] furanyl, thiophene, isoxazolyl, indolyl, R2 is H or alkyl of 1 to 6 carbon atoms; OR R1 and R2 are taken together with the nitrogen atoms to which they are attached to form a compound of Formula (Ia), (Ib), or (le), R3 is - (CH2) m-E- (CH2) m-Z2; E is O, S, -C (0) -, -C (0) -0-, -NH-C (O) -0- or a bond; Z2 is H, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (Ci-Ci2) alkylamino, alkylguanidino of 1 to 12 carbon atoms or an optionally substituted portion selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; R4 is H or - (CHs -A1; A1 is -C (= Y) -N (XXX2), -C (= Y) -X2, -C (= NH) -X2 or X2, Y is O or S; X1 is H, alkyl of 1 to 12 carbon atoms, - (CH2) m-NH- (C6-6) alkyl, - (CH2) mN-di- (d-C6) alkyl c (CH2) ra-aryl X2 is - (CH2) m-Y1-X3 or optionally substituted alkyl of 1 to 12 carbon atoms: Y1 is O, S, NH, C = 0, alkenyl of 2 to 12 carbon atoms having one or more double links, -NH-CO-, -CO-NH-, -NH-CO-O- (CH2) m-, C = C-, S02 or a bond; X3 is H, an optionally substituted portion selected from the group which consists of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -Ci2) alkylamino, -CH-di- (C1-C12) alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo [b] furanyl, quinolinyl, isoquinolinyl, - (CH2 ) m-phenyl, naphthyl, fluorenyl, phthalamidi what, pyrimidinyl, or X1 and X2 are taken together with the nitrogen to which they are bound to form an optionally substituted portion selected from the group consisting of thiazolyl Y2 is CH-X4, N-X4, -C (X4X4), O or S; X4 for each occurrence is independently - (CH2) m-Y3-X5; Y3 is -C (0) -, -C (0) 0- or a bond; X5 is hydroxy, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -C12) alkylamino, or an optionally substituted portion selected from the group consisting of of aryl, aryl (C? -C4) alkyl, furanyl, pyridinyl, indolyl, -CH (phenyl) 2, R5 is alkyl of 1 to 12 carbon atoms, (C0-C6) alkyl-C (O) -O-Z5, (C0-C6) alkyl-C (O) -NH- (CH2) m-Z3 or optionally substituted aryl; Z3 for each occurrence is independently amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C1-C12) alkylamino, -NH-C (O) -O- (CH2) m-phenyl, -NH- C (O) -0- (CH2) m- (C? -C6) alkyl or an optionally substituted moiety selected from the group consisting of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl, and thiophene; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or - (CH2) mZ; Z4 is an optionally substituted portion selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo [b] furan, benzo [b] thiophene, isoxazolyl, Z is H, alkyl of 1 to 12 carbon atoms, (CH2) m-aryl, - wherein an optionally substituted portion is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF3, CN, N3, N02, OH, S02NH2, -OCF3, alkoxy of 1 to 12 carbon atoms, - (CH2) m-phenyl- (X6) n, -S-phenyl- (X6) n, -S- (C1-C12) alkyl, - 0- (CH2) m-phenyl- (X6) n, - (CH2) mC (0) -O- (C? -C6) alkyl, - (CH2) mC (0) - (Cx-C6) alkyl, - 0- (CH2) m-NH2, -0- (CH2) mNH- (d-Cß) alkyl, -0- (CH2) mN-di- ((C? -C6) alkyl) and - (C0-C12) alkyl- (X6) n; X6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, N02, N3, CN, OH, -CF3, -0CF3, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, - (CH2) m-NH2, - (CH2) m-NH- (C6-6) alkyl, - (CH2) mN-di- ((C6-6) alkyl) and - ( CH2) m-phenyl; m for each occurrence is independently 0 or an integer from 1 to 6; and n for each occurrence is independently an integer from 1 to 5; with the proviso that: (a) when R5 is alkyl of 1 to 12 carbon atoms or -C (0) -0-Z5 and Z5 is alkyl of 1 to 12 carbon atoms or optionally substituted aryl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or Z4 and Z4 is thiophene or optionally substituted phenyl, then R3 is not -C (O) -O- (CH2) mZ wherein m is 0 and Z is H or alkyl of 1 to 12 carbon atoms or where 'm is 1 or 6 and Z is H; (b) when R5 is alkyl of 1 to 12 carbon atoms or optionally substituted phenyl; R 6 is H c alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms and R3 is -O- (CH2) -Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; and (c) when R5 is H or alkyl of 1 to 12 carbon atoms; R6 is alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms; and R3 is -O-Z2 or -S-Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl. A preferred compound of Formula I wherein R1 is H; R2 is H; R3 is -CH2-phenyl; R4 is - (O ^ m-A1 where in the definition of R4 is 0, R5 is phenyl, R6 is H, where A1 is -C (= Y) -N (XXX2); Y is O; X1 is H or methyl X2 is - (CH2) m-Y1-Y3, m in the definition of X2 is 0, 1, 2 or 3, Y1 is a bond or O, and X3 is N-methylpyrrolidin-2-yl, diethylamino, pyridinyl, thiophene, imidazolyl, diethoxymethyl, 1-benzyl-piperidin-4-yl, optionally substituted phenyl or Another preferred compound of Formula (I) is where R 1 is H, R 2 is H, R 3 is -CH 2 -phenyl, R 4 is - ( CU2) m-A1 where m in the definition of R4 is 0, R5 is phenyl, R6 is H, where A1 is -C (= Y) -N (X ^ 2), Y is O, X1 is benzyl and X2 is 2-hydroxyethyl; or X1 and X2 are taken together with the nitrogen atom to which they are bound to form where Y2 C-X4 or N-X4; X4 is - (CH2) m-Y3-X5 where m in the definition of X4 is 0 or 1; and X5 is selected from the group consisting of furanyl, benzyl, phenyl, amino, Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is -CH2-phenyl; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl; R6 is H; where A1 is -C (= Y) -X2; Cast; X2 is - (CH2) m-Y1-X3; where m in the definition of X2 is 0, 1 or 2; Y1 is O, -NH-CO-, -CO-NH-, -NH-CO-0-CH2-, S02 or a bond; and X is methyl, furanyl, pentyl, phenyl, indolyl, p-N02-phenyl, naphthyl, fluorenyl, -CH (phenyl) 2, benzothiazolyl, phthalamidyl, N, N-dimethylamino.

Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl or t-Bu; R6 is H; A1 is -C (= Y) -N (X? X2); And it is O or S; X1 is H; X2 is - (CH2) m-? X? 3; m in the definition of X2 is 0, 1 or 2; Y1 is a link; and X3 is phenyl, O-Cl-phenyl, m-Cl-phenyl, p-phenyloxy-phenyl, 2,6-di-isopropylphenyl, m-CF3-phenyl, p-ethoxycarbonyl-phenyl, 2,4-difluorophenyl, m -N02-phenyl, p-benzyloxyphenyl, o-isopropylphenyl, n-hexyl, 4-morpholino, naphthyl or H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl or t-Bu; R6 is H; where A1 is -C (= Y) -X2; And it is 0; X2 is - (CH2) m-? X? 3; where m in the definition of X2 is 0, 1, or 2; Y1 is O, -CO-NH-, -NH-C0-0-CH2- or a bond; and X3 is methyl, 3-pentyl, phenyl, p-N02-phenyl, phthalamidyl, N, N-dimethylamino, p-aminophenyl, fluorenyl or Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl O t -Bu; R6 is H; where A1 is -C (= Y) -N (X ^ 2); And it is 0; X1 is hydrogen; X2 is - (CH2) m-Y1-X3; ... where m in the definition of X2 is 0, 1, 2 or 3; Y1 is O or a link; and X3 is cyclopentyl, 4-0H-butyl, N, N-diethylamino, N-methyl-pyrrolidin-3-yl, -CH (ethoxy) 2, phenyl, p-S02NH2-phenyl, p-OH-phenyl, 0- CF3-phenyl, p-Cl-phenyl, -CH (phenyl) 2, Another compound of Formula (I) is where R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CH ^ m-A1 where m in the definition of R4 is 0; R5 is phenyl or t-Bu; R6 is H; where A1 is -C (= Y) -X2; Y is O; X2 is - (CH2) m-Y1-X3, where m in the definition of X2 is 0, 1, 2 or 3, Y1 is -NH-CO, -C = C-, -C = C- or a bond, and X3 is t-butyl, l-methylcarbonyl-piperidin-4-yl, phenyl, p-Cl-phenyl, m-CF 3 -phenyl, 4-nitro-naphthyl, p-methoxy-phenyl, m- (phenylethyl) -phenyl, indole -3-yl or p-aminophenyl Another preferred compound of Formula (I) is where R 1 is H, R 2 is H, R 3 is -CH 2 -indol-3-yl, - (CH 2) 4 -NH-CO-Ot -Bu or - (CH2) 4-NH2; R4 is - (CHsJm-A1 where m in the definition of R4 is 0; R5 is phenyl, O-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or pN, N-diethylamino-phenyl, R6 is H, where A1 is -C (= Y) N (X ^ 2), Y is O, X1 is H, X2 is - (CH2) m-Y1-X3, where m in the definition of X2 is 0, Y1 is a bond, and X3 is o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-Nitro-phenyl, m-nitro-phenyl, p-nitro-phenyl, o-CF3-phenyl, m-CF3-phenyl, p-CF3-phenyl, pFf enyl, 2,4-di-F-phenyl, 2,5-di-F-phenyl, 2,5-di-methoxy-phenyl, m-OMe-phenyl, p-OMe-phenyl, 2-CF3-4- Cl-phenyl or 3-nitro-4-F-phenyl. Of the compounds mentioned above, it is preferred that when R5 is phenyl and R3 is - (CH2) -indol-3-ylc that the stereochemistry at the carbon to which R3 binds is in the R configuration. Another preferred compound of the Formula ( I) is where R1 is H; R2 is H; R3 is -CH2-indol-3-yl; - (CH2) 4-NH-CO-O-t-Bu or - (CH2) 4-NH2; R4 is - (CH ^ -A1 where m in the definition of R4 is 0, R5 is phenyl, o-methoxyphenyl, P-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or pN, N-diethylamino-phenyl; R6 is H, where A1 is -C (= Y) -X2, Y is 0, X2 is - (CH2) m-Y1-X3, where m in the definition of X2 is 1, Y1 is a bond, and X3 is phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-nitro-phenyl, m-nitro-phenyl, p-nitro-phenyl, o-CF3-phenyl, m-CF3-phenyl, p-CF3-phenyl, oF-phenyl, mF-phenyl, pF-phenyl, N, N-di-methylamino-phenyl, o-OMe- phenyl, m-OMe-phenyl, p-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl or 2, 4-di-F-phenyl.

Of the immediately preceding compounds, when R5 is phenyl or o-OMe-phenyl and R3 is - (CH2) -indol -3-yl, it is preferred that the compounds are the separate enantiomerics (R or S configuration) according to the carbon at which is joined R3. Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is - (CH2) 4-NH-CO-0-t-Bu or - (CH2) 4-NH2; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl; Rs is H; where A1 is -C (= Y) -X2; Cast; X2 is - (CH2) m-Y1-X3; where m in the definition of X2 is 0, 1 or 2; Y1 is S, S02 or a link; and X3 is phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl, 2,4-di-F-phenyl, -furanyl, 2-pyridinyl, 3-pyridinyl, naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 8-quinolinyl, 1-isoquinolinyl, 2-thiophene or 2-pyrimidinyl. Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is - (CH2) 4-NH-CO-0-t-Bu or - (CH2) 4-NH2; R4 is - (CH2) m-A1, where m in the definition of R4 is 0; R5 is phenyl; R6 is H; where A1 is -C (= Y) -X2; Cast; X2 is - (CH2) m-Y ^ X3; where m in the definition of X2 is 0, 1, 2 or 3; Y1 is a link; and X3 is 5-indolyl, 3-indolyl, 4-indolyl, 2-indolyl, 5-OMe-indol-3-yl, 5-OMe-indol-2-yl, 5-OH-indol-2-yl, 5-OH-indol-3-yl, 5- Br-indol-3-yl, 2-Me-indol-3-yl, 2-benzothiophene, 3-benzothiophene, or 2-benzofuran. Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is - (CH2) m-indol-3-yl, - (CH2) - NH-CO-0-t-Bu or - (CH2) 4-NH2; R4 is - (CU2) m-A1 where m in the definition of R4 is 0; R5 is phenyl, o-OMe-phenyl or p-OME-phenyl; R6 is H; where A1 is X2; where m in the definition of X2 is 1, 2 or 3; Y1 is S, O or a link; and X3 is phenyl, O-OH-phenyl, p-OH-phenyl, oF-phenyl, mF-phenyl, pF-phenyl, o-CF3-phenyl, o-OMe-phenyl, m-OMe-phenyl, o-nitro -phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, 2-thiophene , 3, 4, 5-tri-OMe-phenyl, pN, N-dimethylamino-phenyl, p-OCF3-phenyl, p- (3- (N, N-dimethylamino) propoxy) phenyl, 3-F-4-OMe -phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, methyl, n-butyl, n-pentyl, n-hexyl, 3, 3-dimethyl-butyl , benzyl, cyclohexyl or pt-Bu-phenyl. Another preferred compound of Formula (I) is where R1 is H; R2 is H; R3 is - (CH2) 4-NH-CO-0-t-Bu or - (CH2) -NH2; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl; R6 is H; where A1 is X2; X2 is - (CH2) m-? X? 3; where m in the definition of X2 is 1, 2 or 3; Y1 is O or a link; and X3 is phenyl, o-OH-phenyl, p-OH-phenyl, oF-phenyl, mF-phenyl, pF-phenyl, o-CF3-phenyl, o-OMe-phenyl, m-OMe-phenyl, p-OMe phenyl, o-nitro-phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, O-Br-phenyl, m-Br-phenyl, p-Br phenyl, p-phenyl-phenyl, 2-thiophene, 3,4,5-tri-OMe-phenyl, pN, N-dimethylamino-phenyl, p-benzyloxy-phenyl, p-OCF3-phenyl, p- (3- (N, N-dimethylamino) propoxy) phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, 3-indolyl , 6-methoxycarbonyl-indol-3-yl, l-methyl-indol-3-yl, 2-methyl-indol-3-yl, methyl, n-butyl, n-pentyl, n-hexyl, 3, 3-dimethyl -butyl, benzyl, cyclohexyl or pt-Bu-phenyl. Another preferred compound of Formula (I) is where R1 is (CH2) -CO-Z1; R2 is H; R3 is - (CH2) 4-NH-C0-0-t-Bu, - (CH2) 4-NH-CO-0-benzyl, - (CH2) -phenyl or - (CH2) -indol -3-yl, • R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl; R6 is H; wherein Z1 is ethyl, phenyl, p-OMe-phenyl, p-phenyl-phenyl, p-Cl-phenyl, p-Br-phenyl, p-N3-phenyl, pF-phenyl, m-nitro-phenyl, p-nitro phenyl, p-CN-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, N, N-dimethylamino-phenyl, 3-methyl-4-Cl-phenyl or naphthyl; A1 is -C (= Y) -X2; Cast; X2 is - (CH2) m-Y ^ X3; where m in the definition of X2 is 0; Y1 is 0; and X3 is t-Bu. Another compound of Formula (I) is where R1 is - (CH2) -CO- (CH2) m -Z1 where m in the definition of R1 is 0, 1 or 2; R2 is H; R3 is -CH2-indL-3-yl or - (CH2) 4-NH-C0-0-t-Bu; R4 is H or - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl, o-OMe-phenyl, p-nitro-phenyl, p-Br-phenyl, t-Bu, -CH (CH3) 2-CO-NH- (CH2) 2-C0-0-t-Bu, -CH (CH3) 2-C0-NH- (CH2) 3-imidazol-1-yl, -CH (CH3) 2-C0-NH- (CH2) 2-pyridin-2-yl, CH (CH3) 2- C0-NH- (CH2) 3-4-morpholino, -CH (CH3) 2-C0-NH- (CH2) -pyridin-4-yl or CH (CH3) 2-C0-NH- (CH2) 2-N , N-diethylamino; R6 is H; wherein Z1 is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, pF-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p -N3-phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, pN, N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3 , 4-di-F-phenyl, p-OCF3-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, -Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3- (2, 4-di- Cl-phenyl) -isoxazole-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl, A1 is -C (= Y) -X2; Cast; X2 is - (CH2) m-Y1-X3; where m in the definition of X2 is 0; Y1 is O; and X3 is t-Bu. Another preferred compound of Formula (I) is where R1 and R2 are taken together to form a compound of Formula (Ib) or (le); R3 is -CH2-indol-3-yl, - (CH2) -phenyl, - (CH2) -NH-CO-O-benzyl or - (CH2) 4-NH2; R5 is phenyl, o-OMe-phenyl, p-OMe-phenyl, p-Br-phenyl, p-nitro-phenyl, t-Bu or -CH (CH3) 2-CO-NH- (CH2) 2-NH2; R6 is H; R7 is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, pF-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p- N3-phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, pN, N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3, 4-di-F-phenyl, p-0CF3-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, 3- Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3- (2,4-di-Cl) phenyl) -isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl, In another aspect, the present invention is directed to a compound of Formula (II) (ll) the racemic-diastereomeric mixtures and optical isomers of the compounds of the Formula (II), the pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salt of the drug, wherein it represents an optional bond; R1 is H, - (CH2) m-C (0) - (CH2) m -Z1, - (CHa ^ -Z1, - (CHs ^ -O-Z1 or - (C0-C6) alkyl? C (O) -NH- (CH2) m-Z3, Z1 is an optionally substituted moiety selected from the group consisting of alkyl of 1 to 12 carbon atoms, benzo [b] thiophene, phenyl , naphthyl, benzo [b] furanyl, thiophene, isoxazolyl, indolyl, R2 is H or alkyl of 1 to 6 carbon atoms; or R1 and R2 are taken together with the nitrogen atoms to which they are attached to form a compound of the Formula (lia), (Ilb), or (lie), R3 is - (CH2) m-E- (CH2) m-Z2; E is O, S, -C (O) -, -C (0) -0-, -NH-C (0) -0-, -N (CX-C6) alkyl-C (O) -O- or a link; Z2 is H, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -Ci2) alkylamino, alkylguanidino of 1 to 12 carbon atoms or a portion optionally substituted one selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; R4 is H or - (CHsím-A1; A1 is -C (= Y) -NÍX ^ 2), -C (= Y) -X2, -C (= NH) -X2 or X2, Y is O or S; X1 is H, alkyl of 1 to 12 carbon atoms, - (CH2) m-NH- (Cx-Cß) alkyl, - (CH2) mN-di- (C? -C6) alkyl or (CH2) m-aryl; X2 is - (CH2) m-? X? 3 or optionally substituted alkyl of 1 to 12 carbon atoms; Y1 is O, S, NH, C = 0, alkenyl of 2 to 12 carbon atoms having one or more double bonds, -NH-CO-, -CO-NH-, -NH-CO-0- (CH2) m-, C = C-, S02 or a bond; X3 is H, an optionally substituted portion selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -Ci2) alkylamino, -CH-di- (C1-C12) alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo [b] furanyl, quinolinyl, isoquinolinyl, - (CH2) m-phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl, or X1 and X2 are taken together with the nitrogen to which they are bound to form an optionally substituted portion selected from the group consisting of thiazolyl Y2 is CH-X4, N-X "-C (X4X4) O O S; X4 for each occurrence is independently H or - (CH2) m-Y3-X5; Y3 is -C (O) -, -C (0) 0- or a bond; X5 is hydroxy, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C1-C12) alkylamino, or an optionally substituted portion selected from the group consisting of aryl, aryl (C? -C) alkyl, furanyl, pyridinyl, indolyl, piperidinyl, -CH (phenyl) 2, R5 is alkyl of 1 to 12 carbon atoms, (C0-C6) alkyl-C (0) -O-Z5, (C0-C6) alkyl-C (O) -NH- (CH2) m-Z3 or aryl optionally replaced; Z3 for each occurrence is independently amino, alkylamino of 1 to 12 carbon atoms, amino (C1-C12) -alkyl, cycloalkylamino of 5 to 7 carbon atoms, amino (C5-C7) cycloalkyl, N- (C1-C12) alkylamino, N, N-di- (C? -C12) alkylamino, -NH-C (0) -O- (CH2) m-phenyl -NH-C (0) -O- (CH2) m- (Ci-) Cg) alkyl, -CH (phenyl) 2, (C5-C7) cycloalkyl, H2N- (Ci-Ce) alkyl-C (O) - (C? -C3) alkyl (optionally substituted phenyl) - (CH2) m-0-C (O) -NH- (C? -C6) alkyl ^ IC (O) -O- (C? -C6) alkyl or an optionally substituted moiety selected from the group consisting of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl, phenyl, indolyl and thiophene, with the proviso that when m is 0 in the formula for R5 then Z3 is not -NH-C (O) -O- (CH2) m-phenyl or -NH-C (O) -0- (CH2) m- (C? -C3) alkyl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or - (CH2) m -Z; Z4 is an optionally substituted portion selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo [b] furan, benzo [b] thiophene, isoxazolyl, Z5 is H, alkyl of 1 to 12 carbon atoms, or - (CH2) m-aryl; wherein an optionally substituted portion is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF3, CN, N3, N02, OH, S02NH2, -OCF3, alkoxy from 1 to 12 carbon atoms, - (CH2) m-phenyl- (X6) n, -S-phenyl- (X6) n, -S- (C1-C12) alkyl, -0- (CH2) m-phenyl - (X6) n - (CH2) mC (0) -0- (C? -C6) alkyl, - (CH2) mC (O) - (C ± -C6) alkyl, -0- (CH2) m-NH2 , -O- (CH2) mNH- (C? -C6) alkyl, -0- (CH2) mN-di- ((Ci-Cß) alkyl), - (C0-C12) alkyl- (X6) n and - ( CH2) m-phenyl-X7 X6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, N02, N3, CN, OH, -CF3, -0CF3, alkyl from 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, - (CH2) m-NH2, - (CH2) m -NH- (C? -C6) alkyl, (CH2) mN-di- ((C? -C6) alkyl) and - (CH 2) m-phenyl; X7 is -NH-C (= NH HI) -X8, wherein X8 is thiophene, (C? -C6) alkyl or phenyl; m for each occurrence is independently 0 or an integer from 1 to 6; and n for each occurrence is independently an integer from 1 to 5; with the proviso that: (a) when R5 is alkyl of 1 to 12 carbon atoms or -C (0) -0-Z5 and Z5 is alkyl of 1 to 12 carbon atoms or optionally substituted aryl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or Z4 and Z4 is thiophene or optionally substituted phenyl, then R3 is not -C (O) -O- (CH2) mZ wherein m is 0 and Z is H or alkyl of 1 to 12 carbon atoms or where 1 m is 1 to 6 and Z is H; (b) when R5 is alkyl of 1 to 12 carbon atoms or optionally substituted phenyl; R 6 is H c alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms and R3 is -O- (CH2) -Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; and (c) when R5 is H or alkyl of 1 to 12 carbon atoms; R6 is alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms; and R3 is -O-Z2 or -S-Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl. A preferred group of the compounds of Formula (II) has the following formula: where is - CH 2 --NH 2 (CH 2 --NH 2 i (CH 2) 3 --NH 2 or X 1 is - (CH 2) 2 - N (CH 3) 2 and X 2 is benzyl; or X 1 and X 2 are taken together with the nitrogen atom to which They are united to form: Another preferred group of the compound of Formula (II) having the following formula: where ZJ is X1 is - (CH2) 2-N (CH3) 2 and X2 is benzyl; or X1 and X2 are taken together with the nitrogen atom to which they are bound to form Still another preferred group of the compound of Formula (II) having the following formula: wherein X is p-chloro-phenyl, p-methoxy-phenyl, 2,4-difluoro-phenyl, or thienyl. Still another preferred group of the compound of Formula (II) having the following formula: wherein X2 is p-chloro-phenyl, p-methoxy-phenyl, phenyl or thienyl. Still, in addition, a preferred compound of FormulaulcL (II) has the following formula: Still, in addition, another preferred compound of Formula (II) has the following formula: Still another preferred compound of the compounds Formula (II) has the following formula: where Rb is m-nitro-phenyl or 2-phenyl-ethyl, • offend or rofenil. In another aspect, this invention relates to a pharmaceutical composition comprising one or more of a compound of Formula (I) or Formula (II), as defined hereinbefore, and a pharmaceutically acceptable carrier.

In another aspect, the present invention is directed to a method for producing an agonist effect in one or more of the somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound of Formula (I) or Formula ( II) or a pharmaceutically acceptable salt thereof to the subject. In another aspect, the present invention is directed to a method for producing an antagonistic effect in one or more of the somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound of Formula (I) or Formula (I). II) or a pharmaceutically acceptable salt thereof to the subject. In another aspect, the present invention is directed to a method for joining one or more of the somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof to the subject. In another aspect, the present invention is directed to a method for treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, pseudocystis and external and internal pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, diarrhea, AIDS-related diarrhea, chemotherapy-related diarrhea, scleroderma, irritable bowel syndrome, pancreatitis, small bowel obstruction, gastro-oesophageal reflux, deuder-gastric reflux, Cushing's syndrome, gonadotropinoma, hyperparathyroidism, Graves' disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof, which comprises administering a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof to the subject. In another aspect, the present invention is directed to a method for treating diabetes mellitus, hyperlipidemia, insulin insensitivity, syndrome X, angiopathy, proliferative retinopathy, onset phenomenon, nephropathy, peptide ulcers, enterocutaneous and pancreaticocutaneous fistula, voiding syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, tumors that secrete gastrointestinal hormone, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, bleeding of graft spleens and gastrointestinal bleeding in a subject in need thereof, which comprises administering a compound of the formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof to the subject.

In another aspect, the present invention is directed to a method for inhibiting the proliferation of Helicobacter pylori in a subject in need thereof, which comprises administering a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof. to the subject.

DETAILED DESCRIPTION OF THE INVENTION One skilled in the art will recognize that certain substituents listed in this invention may have reduced chemical stability when combined with others or with heteroatoms in the compounds. These compounds with reduced chemical stability are not preferred. In general, the compounds of Formula I or II can be made by processes that include processes known in the chemical art for the production of compounds. Certain compounds for the preparation of the compounds of Formula I or II are provided as further features of the invention and are illustrated by the following reaction schemes and examples. In the above structural formulas and throughout the present application, the following terms have the indicated meanings unless expressly stated otherwise. Alkyl groups are proposed to include those alkyl groups of the desired length in either a straight or branched configuration. Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl and the like. When the definition "C0-alkyl" is presented in the definition, it means a simple covalent bond. The alkoxy groups specified above are proposed to include those alkoxy groups of the desired length in either a straight or branched configuration.

Examples of alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy, and the like. The term halogen or halo is proposed to include the halogen, fluorine, chlorine, bromine and iodine atoms. The term "cycloalkyl" is intended to include a mono-cycloalkyl group or a bi-cycloalkyl group of the indicated number of carbons known to those skilled in the art. The term "aryl" is intended to include aromatic rings known in the art, which may be monocyclic, bi-cyclic or tri-cyclic, such as phenyl, naphthyl and anthracene. The term "heterocycle" includes monocyclic, bi-cyclic and tri-cyclic systems having one or more heteroatoms, such as oxygen, nitrogen and / or sulfur. The ring systems can be aromatic, for example, pyridine, indole, quinoline, pyrimidine, thiophene (also known as thienyl), furan, benzothiophene, tetrazole, dihydroindole, indazole, N-formylindole, benzimidazole, thiazole and thiadiazole. The ring systems can be non-aromatic, for example pyrrolidine, piperidine, morpholine and the like. The experienced chemist will recognize that certain combinations of heteroatom-containing substituents listed in the invention define compounds that will be less stable under physiological conditions. Accordingly, these compounds are less preferred. When a chemical structure as used herein has an arrow emanating from it, the arrow indicates the point of attachment. For example, the structure ^ ^ - ^ ^^ and is a pentyl group. When an arrow is drawn through a cyclic portion, the arrow indicates that the cyclic portion can be attached to any of the loci.

Available binding points, for example, means that the phenyl can bind ortho, meta or para to group X. When the arrow is drawn through a bi-cyclic or tri-cyclic portion, the arrow indicates that the bicyclic or tri-cyclic ring -cyclic can be attached to any of the available joining points in any of the rings, for example, it means that the indole is bound either through the phenyl portion of the ring or the ring portion containing nitrogen. The compounds of the present invention have at least one asymmetric center as indicated by the asterisk in the structural formula (I), (the) and (Ib), previous. Additional asymmetric centers may be present in the molecule depending on the nature of the various substituents in the molecule. Each asymmetric center will produce two optical isomers and it is proposed that all optical isomers, such as separate, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, are included within the scope of the present invention. The present compounds can be generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from the use of inorganic and organic acids. Examples of these acids are hydrochloric, nitric, sulfuric, phosphoric, acetic, propionic, maleic, succinic, D-tartaric, L-tartaric, malonic, methanesulfonic and the like. In addition, certain compounds containing an acid function such as a carboxy can be isolated in the form of their inorganic salts in which the counter-ion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as of organic bases. The pharmaceutically acceptable salts are formed by taking about 1 equivalent of a compound of the Formula (I) or (II) and contacting it with about 1 equivalent of the corresponding, appropriate acid of the salt that is desired. The working up and isolation of the resulting salt is well known to those skilled in the art. As is known in the art, somatostatin agonists and antagonists are useful for treating a variety of medical conditions and diseases, such as inhibition of H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, pseudocystis and external and internal pancreatic ascites, VlPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, diarrhea, diarrhea related to AIDS, diarrhea related to chemotherapy, scleroderma, irritable bowel syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, reflux deudenogastric, and in the treatment of endocrinological diseases and / or such conditions, such as Cushing's syndrome, gonadotropinoma, hyperparathyroidism, Graves' disease, diabetic neuropathy, Paget's disease and polycystic ovarian disease; in the treatment of various types of cancer such as thyroid cancer, hepatoma, leukemia, meningioma and conditions associated with cancer such as cancer cachexia; in the treatment of conditions such as hypotension such as orthostatic hypotension and postprandial hypotension and panic attacks; adenomas that secrete GH (acromegaly) and adenomas that secrete TSH. Activation of the receptor of subtype type 2 and not of type 5 has been associated with the treatment of adenomas secreting prolactin. Other indications associated with the activation of somatostatin subtypes are the inhibition of insulin and / or glucagon and more particularly diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, onset and nephropathy; inhibition of gastric acid secretion and, more particularly, peptic ulcers, enterocutaneous and pancreatic-cutaneous fistula, emptying syndrome, watery diarrhea syndrome, acute and chronic pancreatitis and tumors that secrete gastrointestinal hormones; inhibition of angiogenesis, treatment of inflammatory disorders such as arthritis, chronic rejection of the allograft; angioplasty, prevention of gastrointestinal and graft spleen. Somatostatin agonists can also be used to decrease the body weight in a patient. Accordingly, the compounds of the present invention are useful for the above methods. Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula (I) or (II) in association with a pharmaceutically acceptable carrier. The compounds of this invention may be administered by routes of oral, parenteral (eg, intramuscular, intraperitoneal, intravenous or subcutaneous, or implant), nasal, vaginal, rectal, sublingual or topical administration and may be formulated with pharmaceutically acceptable carriers. to provide appropriate dosage forms for each route of administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one pharmaceutically acceptable carrier such as sucrose, lactose or starch. These dosage forms may also comprise, as is normal practice, additional substances other than these inert diluents, for example, lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Additionally, tablets and pills can be prepared with enteric coatings. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs containing inert diluents commonly used in the art, such as water. In addition to these inert diluents, the compositions may also include adjuvants, such as wetting agents, emulsifying and dispersing agents, and sweetening, flavoring and flavoring agents. Preparations according to this invention for parenteral administration include aqueous or non-aqueous, sterile solutions, suspensions or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and corn oil, gelatin and injectable organic esters such as ethyl oleate. These dosage forms may also contain adjuvants such as preservatives, humectants, emulsifiers and dispersants. They can be sterilized for example by filtration through a filter that retains bacteria, by incorporating sterilization agents in the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in a form of solid compositions, sterile that can be dissolved in sterile water, or some other injectable, sterile medium immediately before use. The compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax. Compositions for nasal or sublingual administration are also prepared with normal excipients well known in the art. Additionally, a compound of this invention can be administered in a sustained release composition such as those described in the following patents. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Patent Application Serial No. 08 / 929,363 filed September 9, 1997 teaches sustained-release, polymeric compositions comprising a bioactive agent and chitosan. U.S. Patent Application Serial No. 08 / 740,778 filed November 1, 1996 teaches sustained release compositions comprising a bioactive agent and cyclodextrin. U.S. Patent Application Serial No. 09 / 015,394 filed January 29, 1998, teaches sustained-release compositions, stunning of a bioactive agent. The teachings of the above patents and applications are incorporated herein by reference. In general, an effective dose of the active ingredient in the compositions of this invention can be varied, however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dose depends on the desired therapeutic effect, the route of administration, and the duration of the treatment, all of which are within the area of knowledge of one skilled in the art. In general, dose levels of between 0.0001 to 100 mg / kg body weight daily are administered to humans and other animals, e.g., mammals. A preferred dose range is 0.01 to 10.0 mg / kg of body weight daily, which can be administered as a single dose or divided into multiple doses.

The compounds of the present invention can be assessed for their stability for binding to a somatostatin receptor subtype according to the following assays. Studies of binding to human somatostatin receptor subtype: The affinity of a compound for human somatostatin subtype 1 to 5 receptors (ssti, sst2, sst3, sst4 and sst5, respectively) is determined by measuring the inhibition of [125I- Tyr11] SRIF-14 in its binding to the transfected CH0-K1 cells. The human sstx receptor gene was cloned as a genomic fragment. A 1.5 kb Pstl-Xmnl segment containing 100 bp of the 5'-untranslated region, 1.17 kb of the entire coding region and 230 bp of the 3'-untranslated region was modified by the addition of the BglII linker. The resulting DNA fragment was subcloned into the BamHI site of a pCMV-81 to produce the mammalian expression plasmid (provided by Dr. Graeme Bell, Univ. Chicago). A clonal cell line stably expressing the ssti receptor was obtained by transfection in CHO-Kl cells (ATCC) using the calcium phosphate co-precipitation method (1). Plasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal cell lines were selected in RPMI 1640 medium containing 0.5 mg / ml of G418 (Gibco), ring cloned, and expanded in culture. The human somatostatin sst2 receptor gene, isolated as a 1.7 kb BamHI-HindIII genomic DNA fragment and subcloned into the plasmid vector pGEM3Z (Promega), was kindly provided by Dr. G. Bell (University of Chicago). The mammalian cell expression vector is constructed by inserting the 1.7 kb BamHI-HindII fragment into compatible endonuclease restriction sites in the pCMV5 plasmid. A clonal cell line is obtained by transfection in CHO-Kl cells using the calcium phosphate co-precipitation method. Plasmid pRSV-neo is included as a selectable marker. The human sst3 was isolated in a genomic fragment, and the entire coding sequence was contained within a 2.4 kb BamHl / HindIIIv fragment. The mammalian expression plasmid pCMV-h3 was constructed by inserting a 2.0 kb NcoI-HindIII fragment into the EcoR1 site of the pCMV vector after modification of the ends and the addition of EcoRl linkers. A line of clonal cells stably expressing the sst3 receptor was obtained by transfection in CHO-Kl cells (ATCC) using the calcium phosphate co-precipitation method. Plasmid pRSV-neo (ATCC) was included as a selectable marker. The clonal cell lines were selected in RPMI 1640 medium containing 0.5 mg / ml of G418 (Gibco), ring cloned, and expanded in culture. The human sst receptor expression plasmid, pCMVC-HX was provided by Dr. Graeme Bell (University of Chicago). The vector contains the genomic fragment of Nhel -Nhel of 1.4 kb that codes for human sst4, 456 bp of the 5'-untranslated region and 200 bp of the 3'-untranslated region, was cloned in the Xbal / EcoRl sites of PCMV-HX. A line of clonal cells stably expressing the sst4 receptor was obtained by transfection in CHO-Kl cells (ATCC) using the calcium phosphate coprecipitation method. Plasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal cell lines were selected in RPMI 1640 medium containing 0.5 mg / ml of G418 (Gibco), ring cloned, and expanded in culture. The human sst5 gene was obtained by PCR using a genomic clone? as a template, and kindly provided by Dr. Graeme Bell (University of Chicago). The resulting 1.2 kb PCR fragment contained 21 base pairs of the 5'-non-translated region, the entire coding region and 55 bp of the 3'-untranslated region. The clone was inserted into the EcoRl site of the plasmid pBSSK (+). The insert was recovered as a 1.2 kb HindIII-Xbal fragment to subclone into the mammalian expression vector pCVM5. A line of clonal cells stably expressing the sst5 receptor was obtained by transfection in CHO-Kl cells (ATCC) using the calcium phosphate co-precipitation method. Plasmid pRSV-neo (ATCC) was included as a selectable marker. The clonal cell lines were selected in RPMI 1640 medium containing 0.5 mg / ml of G418 (Gibco), cloned in ring and expanded in culture. CHO-Kl cells expressing one of the human sst receptors were cultured in RPMI 1640 containing 10% fetal calf serum and 0.4 mg / ml geneticin. The cells were harvested with 0.5 mM EDTA and centrifuged at 500 g for about 5 minutes at about 4 ° C. The pellet was resuspended in 50 mM Tris, pH 7.4 and centrifuged twice at 500 g for about 5 minutes at about 4 ° C. The cells were used by sonication and centrifuged at 39,000 g for about 10 minutes at about 4 ° C. The pellet was resuspended in the same buffer and centrifuged at 50000 g for about 10 minutes at about 4 ° C and the membranes in the resulting pellet were stored at -80 ° C. Competitive inhibition experiments of the binding of [125 I-Tyr1: L] SRIF-14 are run in duplicate in 96-well plates of polypropylene. Cell membranes (10 μg protein / well) were incubated with [125 I-Tyr11] SRIF-14 (0.05 nM) for approximately 60 minutes at approximately 37 ° C in 50 mM HEPES (pH 7.4), 0.2% BSA, 5 mM MgCl 2, Trasilol 200 KlU / ml, 0.02 mg / ml bacitracin and 0.02 mg / ml phenylmethylsulfonyl fluoride. The binding of free [125I-Tyr11] SRIF-14 is separated by immediate filtration through a GF / C glass fiber filter plate (Unifilter, Packard) pre-wetted with 0.1% polyethylenimine (PEI), using a cell harvester Filtermate 196 (Packard). The filters are washed with 50 mM HPES at about 0-4 ° C for about 4 seconds and titrated for radioactivity using a Packard Top-Count counter. The specific unit is obtained by subtracting the non-specific binding (determined in the presence of 0.1 μM SRIF-14) from the total binding. The binding data is analyzed by a computer-aided non-linear regression analysis (CDM) and the values of the inhibition constant (Ki) are determined. The determination of whether a compound of the present invention is an agonist or an antagonist is determined by the following assay. Functional Assay: Inhibition of the intracellular production of cAMP: CHO-Kl cells expressing the human somatostatin receptor subtypes (SRIF-14) are seeded in 24 cavities tissue culture multilayer in RPMI 1640 medium with 10% FCS and 0.4 mg / ml of geneticin. The medium is changed the day before the experiment. Cells at 10 5 cells / well are washed twice by 0.5 ml and fresh RPMI with 0.2% BSA supplemented with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (1) and incubated for about 5 minutes at about 37 ° C. • The production of cyclic AMPC is stimulated by the addition of 1 mM forskolin (FSK) for about 15-30 minutes at about 37 ° C. • The agonist effect of a compound is measured by the simultaneous addition of FSK (1 μM), SRIF-14 (10"12M a "6M and one test compound (10" 10M to 10"5M) • The antagonistic effect of a compound is measured by the simultaneous addition of FSK (1 μm), SRIF-14 (from 1 to 10 nM) and a Test compound (10"10M to 10 ~ 5M). • The antagonistic effect of a compound is measured by the simultaneous addition of FSK (1 μm), SRIF-14 (from 1 to 10 nM) and a test compound (10"10M to 10 ~ 5M). remove and add 200 ml of 0.1 N HCl cAMP is measured using the radioimmunoassay method (Kt FlashPlate SMP001A, New England Nuclear) The compounds of the present invention are synthesized according to the following procedures and examples.

SYNTHESIS OF BROMOCETONAS: General Procedure: Two different methods can be applied: starting either from a carboxylic acid or an arylketone. First method: Starting from a carboxylic acid (Macholan, L .: Skursky, L. Chem. Listy, 1955, 49, 1385-1388 Bestman, HJ, Seng F., Chem. Ber., 1963, 96, 465 -469). OR First a carboxylic acid is converted to an acyl chloride using oxalyl chloride or thionyl chloride or activated as an anhydride mixed with an alkylchloroformate (isobutylchloroformate (Krantz, A., Copp JJ Biochemistry, 1991, 30, 4678-4687) or ethylchloroformate (Podiech, J. Seebach, D., Liebigs Ann., 1995, 1217-1228)) in the presence of a base (triethylamine or N-methyl-morpholine). The activated carboxyl group is then transformed into a diazoketone ring using ethereal diazomethane or trimethylsilyldiazomethane (Aoyama, T., Shiori, T., Chem.

Pharm. Bull., 1981, 29, 3249-3255) in an aprotic solvent such as diethyl ether, tetrahydrofuran or acetonitrile. The bromination is then carried out using a bromination agent such as HBr in acetic acid, hydrobromic acid in water or a diethyl ether. Preparation 1 l-bromo-3- (4-chloro-phenoxy) -3-methyl-butan-2-one To a solution of chloro-4-phenoxy-2-isobutyric acid (2.15 g, 10 mmol) in 10 ml of anhydrous dichloromethane at about 0 ° C were added oxaolyl chloride (5.5 ml, 11 mmol of a 2M solution in dichloromethane) and DMF (2 drops, catalytic amount) via a septum under nitrogen atmosphere. The solution was stirred and allowed to warm to room temperature for about 3 hours. Concentration under reduced pressure gave the crude acid chloride which was used directly without further purification. The acyl chloride was added dropwise at about 0 ° C to a solution of TMSCHN2 (11 mL, 22 mmol) in THF-acetonitrile (1: 1, 10 mL). The mixture was stirred at about 25 ° C for about 1 hour and then evaporated in vacuo. A solution of diazoketone in dichloromethane (10 ml) was added dropwise over about 10 minutes to a vigorously stirred mixture of concentrated hydrobromic acid (5 ml) in dichloromethane (20 ml). Nitrogen was emitted and a slight increase in temperature occurred. After stirring for approximately 10 additional minutes, the mixture was diluted and the organic layer was washed with water (3 times, 20 ml), dried over magnesium sulfate and evaporated. Flash chromatography of the residue by diluting with AcOEt / heptane (1: 4) gave the desired product in 79% yield (2.3 g). 1 H NMR in CDCl 3 (100 MHz) d: 7.05 (m, 4 H, arom.H), 4.41 (s, 2 H, CH 2), 1.53 (s, 6 H, 2 CH 3).

Preparations 2-6 The following compounds were prepared in a manner analogous to the procedure described for Preparation 1: O .A * *. Compounds already described in literature. Second method: Starting from a methyl-ketone.

A methyl ketone is converted to a bromoketone by using different bromination agents: -CuBr2 (King, L.C., Ostrum, G.K., J. Org, Chem, 1964, 299, 3459-3461) heated in AeOEt or dioxane. - N-bromosuccinimide in CC14 - Bromine in glacial acetic acid or sulfuric acid - Phenyltrimethylammonium tribromide (Sánchez, JP, Parcel, RP, J. Heterocyclic Chem., 1988, 25, 469-474) at 20-80 ° C in a aprotic solvent such as THF. - Use of a polymer-supported bromination agent such as perbromide in Amberlyst A-26, poly (vinylpyridinium-hydrobromide-perbromide) resin (Frechet, JMJ, Farrall, MJ, J. Macromol., Sci. Chem., 1977, 507 -514) in a protic solvent such as methanol at about 20-35 ° C for about 2-100 h.

Preparation 7 1-Bromo-2- (3,4,5-trimethoxy-phenyl) -ethanone To a solution of 3,4-trimethoxyacetophenone (2.1 g, 10 mmol) in methanol (30 ml) is added pyridine hydrobromide perbromide polymer (1.4 equivalent). The resulting mixture is stirred at room temperature for about 2 hours and the reaction is stopped by filtration. The polymer is washed with methanol and the filtrate is evaporated in vacuo. The product is then purified by flash chromatography (AcOEt / Heptane, 1: 4) to give 1.5 g (53%) of a white solid. NMR? U on CDC13 (100 MHz) d: 7.2 (s, 2H, H. arom.), 4.4 (s, 2H, CH2), 3.9 (m, 9H, 3 OCH3).

Preparations 8-17 The following compounds were prepared in a manner analogous to the procedure described in Preparation 7.

OR * Compound already described in literature.

SYNTHESIS OF IMIDAZOLYL COMPOUNDS General Procedure: An amino acid is transformed to its cesium salt using cesium carbonate in a polar solvent such as DMF / H20 (1: 1) or EtOH / H20 (1: 1). An ester is then obtained using an appropriate bromoacetone in a polar aprotic solvent such as dry DMF. The formed cesium bromide is completely filtered and ammonium acetate is added in an aprotic solvent having a high boiling point such as xylene or toluene or in a protic acid solvent such as acetic acid. The mixture is refluxed using a Dean-Stark trap for approximately 0.5-10 hours. In the scheme below, PG is a protecting group, preferably a carbamate, such as t-Boc or benzylcarbamate.

Example 1 2-. { (SS) -1- [terbutoxycarbonylamino] -2- [(1H) -indol-3-yl] ethyl} -4- (2-methoxyphenyl) -1H-imidazole: A solution of Boc- (D, L) -Trp-OH (10 g, 32.8 mmol) and cesium carbonate (0.5 equivalents, 5.34 g) in EtOH / H20 (1: 1, 70 ml) was stirred for about 30 minutes at room temperature and then concentrated in vacuo at about 40 ° C. To the resulting salt in 40 mL of dry DMF was added 40 mL of a solution of 2-bromo-2'-methoxyacetophenone (7.66 g, 1 equivalent) in dry DMF. The mixture is stirred for about 1 hour at room temperature under argon and then concentrated under reduced pressure. Ethyl acetate (100 ml) was added, the mixture was filtered and CsBr was washed with ethyl acetate. The filtrate is then concentrated under reduced pressure. A solution of the above filtrate and ammonium acetate (50.5 g, 20 equivalent) in xylene (240 ml) was refluxed for about 3 hours at about 150 ° C. Excess NH40Ac and H20 were removed using a Dean-Stark trap. The progress of the reaction was monitored by t.l.c. (eluent CH2Cl2: MeOH, 95: 5). The mixture was then concentrated under reduced pressure.

The resulting residue was dissolved in ethyl acetate (100 ml) and washed with saturated aqueous NaHCO 3 solution until basic pH, and with brine until pH neutral. The organic layer was then dried over MgSO 4 and concentrated under reduced pressure. Purification of the resulting residue by flash chromatography (eluent: CH2Cl2: MeOH, 95.5) gave the desired compound (8.7 g, 61% yield). NMR (R, CDC13, 100 MHz) d: 8.00 (s, 1H, NH), 7.80 (m, 2H arom.H), 7.20 (m, 9H, arom.H, NH), 5.40 (m, 1H, NH ), 5.10 (m, 1H, CH), 3.80 (s, 3H, 0CH3), 3.50 m, 2H, CH2), 1.50 (s, 9H, 6 CH3). LC / MS: m / z = 433.3 (M + H). Example 2 N- [2-tert-butoxycarbonylamino-ethyl] -2-. { 2- [(SS) -1- (terbutoxycarbonylamino) -2- (1H) -indol-3-yl) ethyl] -1H-imidazol-4-yl} -isobutyramide: A solution of 2- methyl acid ester. { 2- [(SS) -1- (terbutoxycarbonylamino) -2- (indol-3-yl) ethyl] -1H-imidazol-4-yl} -2-methyl-propionic, 1 (2.6 g, 6 mmol), prepared according to the procedure described in Example 1 and LiOH.H20 (1.7 g, 6.6 equivalent) in THF (50 ml) were stirred at approximately 80 °. C for about 3 hours. The progress of the reaction was monitored by t.l.c. (CH2C12: MeOH, 95: 5). The resulting mixture was then concentrated in vacuo. Approximately 50 ml of water was added to the residue which was then acidified with glacial acetic acid to about pH 5. The reaction product was then extracted with ethyl acetate (3 x 50 ml) and washed with brine to neutral pH. The organic layer was dried with MgSO 4 and concentrated under reduced pressure. The resulting intermediate 2 was obtained after crystallization from diethyl ether in a yield of 80% (2 g). H NMR (400 MHz, DMSO) d: 10.9 (s, 1H, NH), 7.1 (m, 7H, arom.H), 5.00 (m, 1H, CH), 3.3 (m, 2H, CH2), 1.3 (m, 15H, 5 CH3). LC / MS: m / z = 525.1 (M + TFA), m / z = 413.2 (M + H). The acid 2-. { 2- [(SS) -1- (terbutoxycarbonolamino) -2- [(1 H) -indol-3-yl} ethyl] -1H-imidazole -4 -yl} -2 -method -propionic 2 can be activated preferentially by carbonyldiimidazole in an aprotic solvent such as THF or DMF at about 20-100 ° C for about 1-4 hours.

A solution of acid 2 (1 g, 2.4 mmol) and carbonyldiimidazole (0.39 g, 2.4 mmol) in dry THF (20 ml) was stirred for about 1 hour at room temperature (25 ° C). N-Boc-ethylene diamine (0.43 g, 2.7 mmol) was added and the mixture was stirred for about 1 hour at about 25 ° C. The mixture was diluted with ethyl acetate (100 ml) and washed with saturated aqueous NaHCO 3 solution (2 x 50 ml) and brine until pH neutral. The organic layer was then dried with MgSO 4 and concentrated in vacuo. Purification of the resulting residue by flash chromatography (CH2C12: MeOH, 95: 5) gave the desired product 3 in 77% yield (1 g). NMRH (400 MHz, DMSO) d: 11.6 (s, 1H, NH), 10.7 (s, 1H, NH), 7.00 (m, 9H, arom.H, NH), 4.8 (m, 1H, CH), 3.00 (m, 6H, 3 CH2), 1.3 (m, 24H, 8 CH3). LC / MS: m / z = 667.3 (M + TFA), 555.3 (M + H). Examples 3-1178 The following compounds were prepared analogously to the procedure described for Example 1 or 2 using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. technical or as permitted by the teachings in the present. Each combination of R3, R5 shown below, were or can be synthesized, therefore, the number of examples is calculated by multiplying (PG (2 substituents) R3 (12 substituents) (R5 (49 substituents)) = 1176.

PG can also be hydrogen in the previous formula * for this substituent, the corresponding imidazole derivative was obtained after deprotection via. catalytic hydrogenation of the benzyloxyphenyl substituent. ** for this substituent, the corresponding imidazole derivative was obtained after deprotection via catalytic hydrogenation of the nitrophenyl substituent.

SYNTHESIS OF AMIDAS FROM IMIDAZOLILO INTERMEDIATE COMPOUNDS General Procedure: The carboxylic acids are activated overnight at room temperature with carbonyldiimidazole in an aprotic solvent such as chloroform, THF or THF / DMF before the addition of an amino start material as shown above followed by 12-15 hours additional agitation. The excess acylating agent is rapidly cooled with aminomethylated resin for about 12-15 hours and then purified on a silica gel pad with dichloromethane or ethyl acetate as eluent. For protected basic derivatives (R3 (CH2) 4NHBoc and / or X2 containing the NHBoc group), the corresponding deprotected compounds were obtained after treatment under acid condition (DCM / TFA 10%) to remove the Boc group.

Example 1179 2-. { (SS) -1- [(2-furanyl) carbonylamino] -2- [indol-3-yl] ethyl} -4- phenyl-lH-imidazole (C24H20N4O2, MW = 396.45): The 2-furancarboxylic acid (12.6 mg, 0.11 mmol) was activated overnight at approximately 22 ° C with carbonyldiimidazole (0.11 mmol, 0.2 M in chloroform), 2-. { (SS) -l-amino-2- [indol-3-yl] ethyl} -4-phenyl-1H-imidazole (0.1 mmol, 0.5M in chloroform) was added to the medium and the mixture was stirred for about 12 hours at about 22 ° C. Then aminomethylated resin (50-60 mg, 1.2 mmol / g, Novabiochem) was added in order to rapidly cool the excess acylating agent for about 12 hours. The purification in silica gel pad (200 mg, Altech) with ethyl acetate as eluent gave the expected product (37.2 mg, 94%) XH NMR (CDC13, 100 MHz) d: 8.36 ((br s, 1H); 7.67-6.4 (m, 16H) , 5.58 (qd, J = 7.1 Hz, 1H); 3.6 (ABX system, 2H), LC / MS: m / z = 397 (M + H).

Examples 1180-3615 The following compounds were prepared in a manner analogous to the procedure described for Example 1179 using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to methods known to those skilled in the art. as allowed by the teachings in the present. Each combination of R3, R5 and X2, shown below, were or can be synthesized, therefore, a number of examples is calculated by multiplying (R3 (4 substituents)) (R5 (7 substituents)) (X2 (87 substituents)) = 2436. r ~ & cr rj ^ y I heard -xxT ° x r T SYNTHESIS OF UREAS AND TIOUREAS FROM INTERMEDIATE IMIDAZOLYL COMPOUNDS From isocyanates and isothiocyanates: Y is O or S General Procedure: the isothiocyanate isocyanates were stirred overnight at room temperature with an imidazolyl intermediate in an aprotic solvent similar to dichloromethane, chloroform c chloroform / DMF. The reaction is rapidly quenched by the addition of aminomethylated resin for about 12-15 hours and purified on a silica gel pad with ethyl acetate as eluent.

For protected basic derivatives (R3 (CH2) 4NHBoc), the corresponding deprotected compounds were obtained after treatment under acid condition (CDM / TFA 10%) to remove the Boc group.

Example 3616 2-. { (IR) -1- [(2,4-difluorofenyl) aminocarbonylamino] [2 - [indol-3-yl] ethyl} -4-phenyl-lH-imidazole (C26H21F2N50, MW 457.49): 2,6-difluorophenylisocyanate (36 μL, 0.3 mmol) and 2- were stirred overnight. { (1 R) -l-amino-2- [indol-3-yl] ethyl} -4-phenyl-lH-imidazole (60.4 mg, 0.2 mmol) in 2 mL of anhydrous dichloromethane. Filtration and purification by flash chromatography on silica gel (ethyl acetate / heptane 1: 1 as eluent) gave the expected product as a white powder (27 mg, 30%). NMR -? (DMSO D6, 400 MHz) d: 12.03 (s, 1H); 10.77 (s, 1H); 8.47 (s, 1H); 8.1 (dd, 1H); 7.8-6.92 (m, 14H); 5.11 (dd, J = 7 and 14 Hz, 1H); 3.3 (m, 2H). LC / MS: m / z = 458 (M + H).

Examples 3617-4435 The following compounds were prepared analogously to the procedure described for Example 3616, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to the methods known to those skilled in the art. technical or as permitted by the teachings in the present. Each combination of R3, R5 and X2 with Y is 0 or X2 with Y is S, shown below, were or could be synthesized, therefore, the number of examples is calculated by multiplying (R3 (3 substituent)) (R5 ( 7 substituents)) (X2 (39 substituents)) = 819.

X when Y is 0: x .A z ^ r X when Y is S: From intermediate compounds of carbamate and primary and secondary amines: General Procedure: The preparation of intermediate carbamate compounds is described in the literature (Takeda, K. et al., Tetrahedron Letters 1983, 24, 4569-4572; Nimura, N et al., Anal. Chem. 1986, 58, 2872-2375) from amino and N, N'-disuccinimidylcarbonate derivatives in acetonitrile at room temperature.

Example 4436 2 -. { (IR) -1 - [(2,5-dioxo-pyrrolidinyloxy) carbonylamino] -2 - [indol-3-yl] et il} -4-phenyl-1H-imidazole (C24H2? N504, MW = 443.46): 302. 4 mg (1 mmol) of 2-. { (IR) -l-amino-2- [indol-3-yl] ethyl} 4-phenyl-1H-imidazole previously dissolved in 20 mL of anhydrous acetonitrile was added dropwise to a solution of N, N '-dissucinimidylcarbonate (528 mg, 2 mmol, DSC) in 20 mL of anhydrous acetonitrile for 1.5 hours. After an additional 4 hours of stirring at room temperature, the solvent was evaporated in vacuo and the residue redissolved in 30 mL of chloroform. The excess DSC was then discarded and the organic layer was washed cor. Water (4 x 30 mL) was dried over MgSO4 and concentrated to. obtain a coffee solid (215 mg, 49%). X H NMR (CDC13, 100 MHz) d: 8.22 (br s, 1H); 8.1-7.08 (m, 12H); 5.9 (br s, 1H); 4.97 (dd, 1H, J = 3.6 and 9.3 Hz, 1H); 3.75 (dd, 1H, J = 3.6 and 14.8 Hz, 1H); 3.06 (dd, 1H, J = 9.7 and 14.6Hz, 1H); 2.96 (s, 2H); 2.89 (s, 2H). LC / MS: m / z = 329 ((M + H) -SuOH.

General Procedure: A primary or secondary amine is stirred for about 2-15 hours at room temperature with a carbamate intermediate in an aprotic solvent such as acetonitrile. Then tetrahydrofuran and aminomethylated resin are added and the reaction is then stirred for about 12-15 hours. The ureas are isolated after filtration, rinsed with ethyl acetate and evaporated in vacuo. For protected basic derivatives (R3 (CH2) NHBoc), the corresponding deprotected compounds were obtained after treatment under acid condition (DCM / TFA 10%) to remove the Boc group.

Example 4437 2-. { (IR) -1- [(Benzylamino) carbonylamino] -2- [indol-3-yl] ethyl} 4-phenyl-lH-imidazole (C27H25N50, MW = 435.53): Benzylamine (5 μl, 50 mmol) and 2- were stirred. { (IR)) -l-amino-2- [indol-3-yl] ethyl} -4-phenyl-1H-imidazole (24 mg, 54 mmol) for about 2 hours at room temperature in anhydrous acetonitrile. Then aminomethylated resin (50 mg, 0.75 mmol / g, Novabiochem) was added and after further stirring overnight, the title product was obtained by filtration on silica gel pad (200 mg) and evaporated in vacuo as a brown powder (20 mg, 92%). RMN ^? (DMSO D6, 100 MHz) d: 10.8 (br s, 1H); 7.9-6.88 (m, 17H); 6.53 (m, 2H); 5.12 (dd, J = 6 and 14.6 Hz, 1H); 4.28 (m, 2H); 3.25 (m, 2H). LC / MS: m / z = 436 (M + H).

Examples 4438-8469 The following compounds were prepared in a manner analogous to the procedure described for Example 4437, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to methods known to those skilled in the art. technical or as permitted by the teachings in the present. Each combination of R3, R5 and NX1X2, shown ^^^ j | £ * te subsequently, were or can be synthesized, therefore, the number of examples is calculated by multiplying (R3 (3 substituents)) (R5 (12 substituents)) (NX ^ 2 (112 substituents) ) = 4032.

X ^ N: Secondary amines SYNTHESIS OF SECONDARY AMINES FOR REDUCTIVE AMINATIONS OF IMIDAZOLYL INTERMEDIATE COMPOUNDS (Kaldor, S.W .: Siegel, M.G., Fritz, J.E .: Dressman, B.A. Hahn, P.J. Tetrahedron Letters 1996, 37, 7193-7196) 3) Carboxaldehyde Resin, DCM General Procedure: Condensation of aldehydes with an imidazolyl intermediate in a protic solvent such as methanol yields imines that are reduced er. the presence of AMBERLITE® IRA-40 borohydride. The slurry is then stirred overnight and the excess amino intermediate is cooled, rapidly by the addition of dichloromethane and Wang resin of aldehyde. After further stirring overnight, the mixture is filtered, evaporated and purified by silica gel pad with acetate; ethyl as eluent. For protected basic derivatives (R3 (CH2) 4NHBoc), the deprotected compounds, correspondingly, were obtained after treatment under acid condition (DCM / TFA 10%) to remove the Boc group.

Example 8470 2-. { (IR) -1 [(4-methoxybenzyl) amino] -2- [indol-3-yl] ethyl} -4-phenyl-lH-imidazole (C27H26N40, MW = 422.54): They were shaken 2-. { (IR) -l-amino-2- [indol-3-yl] ethyl} - 4-phenyl-lH-imidazole (36.3 mg, 0.12 mmol) and p-anisaldehyde (12 μL, 0.1 mmol) in 1 mL of methanol for about 2 hours at about 22 ° C. Then borohydride resin (76 mg, 2.5 mmol / g, AMBERLIT® IRA-400) was added and the slurry was stirred overnight before the addition of dichloromethane (1 mL) and Wang's aldehyde resin (31 mg, 3.22). mmol / g, Novabiochem). After about 8 hours of stirring, the slurry was then filtered and evaporated in vacuo to obtain a yellow solid (32.2 mg, 76%). NMR "" "H (CDC13, 100 MHz) d: 8.86 (br s, 1H); 7.73-6.68 (m, 15H); 4. 62 (s, 1H); 4.33 (dd, J = 4.7 and 8.5 Hz, 1H); 3.81 (s, 2H); 3.74 (s, 3H); 3.27 (ABX system, 2H); 2.26 (s, 1H). LC / MS: m / z = 423 (M + H).

Example: 8471-9331 The following compounds were prepared analogously to the procedure described for Example 8470, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. skilled in the art or as permitted by the teachings herein. Each combination of R3, R5 and A1, shown below, was or can be synthesized, therefore, the number of examples is calculated by multiplying (R3 (3 substituents)) (R5 (7 substituents)) (X2 (41 substituents)) = 861. ^ & crjy and ^ ycr A '. MeO MeO. ~ N H SYNTHESIS OF AMIDINAS BY CONDENSATION OF AN IMIDAZOLYL WITH THIOIMIDATES A series of g ^ L ^^ X thioimidates by condensation of thioamides and iodomethane in acetone at room temperature. The precipitate was collected and rinsed with acetone. The thioimidates formed in this manner were used without further purification. General Procedure: The thioimidates were stirred overnight at room temperature with an amino intermediate in 2-propanol or 2-propanol / DMF before the addition of tetrahydrofuran and aminomethylated resin. Further stirring overnight followed by filtration and washing with ethyl acetate yields an iodohydrated amidine after evaporation in vacuo. For the protected basic derivatives (R3 (CH2) 4NHBoc), the corresponding deprotected compounds were obtained after treatment under acid condition (DCM / TFA 10%) to remove the Boc group.

Example 9332 2- Hydrochloride. { (IR) -1- [(2-thienyl (imino) methyl) amino] -2- [indol-3-yl] ethyl} -4-phenyl-lH-imidazole (C24H2? N5S. H, MW 539.43): They were shaken 2-. { (IR) -l-amino-2- [indol-3-yl] ethyl} -4-phenyl-1H-imidazole (15.1 mg, 0.05 mmol) and S-methyl-2-thiophethiocarboxamide iodidohydrate (13 mg, 0.06 mmol) in 1 mL of 2-propanol for approximately 16 hours. Then aminomethylated resin (50 mg, 1.31 mmol / g, Novabiochem) was added and after further stirring overnight, a brown solid (19.8 mg, 84%) was isolated by filtration and evaporation in vacuo. NMR "" "H (MeOD, 100 MHz) d: 8.15 (m, 1H); 7.84-6.96 (m, 13H); 5.3 (m, 1H); 3.61 (m, 2H). LC / MS: m / z = 412 (M + H).

Examples 9333-9920 The following compounds were prepared analogously to the procedure described for Example 9332, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to the methods known to those skilled in the art. technical or as permitted by the teachings in the present. Each combination of R3, R5 and X2, shown below, was or can be synthesized, therefore, the number of examples is calculated by multiplying (R3 (7 substituents)) (R5 (7 substituents)) (X2 (12 substituents) ) = 588.

Rs: SYNTHESIS OF AMIDINAS BY CONDENSATION OF AN ANILINE WITH THIOIMIDATES Examples 9921-9926 Analogously, the following examples were prepared according to the procedure described for Example 9332, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to the methods known to those skilled in the art. skilled in the art or as allowed by the teachings herein. Each combination of R4 and X7, shown below, were or can be synthesized, therefore, the number of examples is calculated by multiplying (R4 (2 substituents)) (X7 (3 substituents)) = 6. * j¡ * A ^ ^ R "H. XA N-ALKYLING OF IMIDAZOLE DERIVATIVES General Procedure: A solution of an imidazole intermediate, an alkylating agent such as an a-bromoacetone, an a-bromoester, an aryl bromide or alkyl or a sulfonyl chloride, in the presence of an organic or non-organic base which may or may not be supported on a resin such as polystyrene resin, in an aprotic solvent type THF, CH3CN, DMF is heated at 20-80 ° C for 2-48 hours. The resulting N-alkylated compound can be isolated either by aqueous processing followed by flash chromatography on silica gel, or It was added by adding a polymer-supported nucleophile to the reaction mixture (to trap the excess of electrophile) such as aminomethyl- or thiomethyl-polystyrene resin followed by filtration and then rapid purification of the resulting residue on a pad. of silica gel (using Alltech silica cartridge and Alltech distributor).

Example 9927 2- [1 (S) -. { 1, 1-dimethylethoxy) carbonylamino} -2-phenylethi] -1- (2-oxo-butyl) -4-phenyl-1H-imidazole To a solution of 2- [1 (S) -. { (1,1-di-methylethoxy) carbonylamino} -2-phenylethyl] -4-phenyl-1H-imidazole (100 mg, 1 equivalent) in DMF (2 mL) were added successively morpholinomethyl-polystyrene resin (Novabiochem, loading 3.51 mmol / g, 159 mg, 2 equivalents) and 1-bromo-2-butanone (28 mL, 2 equivalents). After about 18 hours of stirring at about 20 ° C, 2 mL of DMF was added to the reaction mixture followed by aminomethyl polystyrene resin (Novabiochem, loading: 1.73 mmol / g, 319 mg). The mixture was stirred overnight at 20 ° C and filtered. The filtrate was concentrated under reduced pressure and then purified by rapid filtration on a silica gel pad (Alltech silica cartridge) with ethyl acetate as eluent to yield 107 mg (90% yield) of the title compound. 1 H NMR (400 MHz, CDCl 3) d: 7.80-6.98 (m, 11H, arom.H), 5.45 (d, 1H, NH), 4.80 (m, 1H, CH), 4.40 (AB, J = 18Hz, NCH2CO ), 3.33 (m, 2H, CH2Ph), 2.25 (m, 2H, CH2CH3), 1.0 (t, 3H, CH3). LC / MS: calculated MW = 433.5, m / z = 434.2 (M + H), m / z = 432.2 (M-H).

Examples 9928-12307 The following compounds were prepared analogously to the procedure described for Example 9927, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to the methods known to those skilled in the art. technical or as permitted by the teachings in the present. Each combination of R3, R5 and R1, shown below, were or can be synthesized, therefore, the number of examples is calculated by multiplying (R1 (34 substituents. {See definitions of Z1.})) (R3 ( 5 substituents)) (R5 (14 substituents)) = 2380 R1: "" 'N ^ O * ^ HN' D ' * In the case of bromide derivatives, cesium carbonate was used in place of morpholinomethylpolystyrene resin and thio ethyl resin was used in place of ammonitic ream. Z1 -O-CN NO ? , -? N ?! -f -O &, XX »- ^ ° 10 IMIDAZO-PIRAZINAS General Procedure: The intermediate compound (a) is treated with a solution preferably acidic TFA in DCM at about 20-30 ° C for about 1-4 hours. The mixture is then concentrated under reduced pressure to produce a dihydro-imidazo-pyrazine. Example 12308 5, 8-dihydro-8- (3-indole) -methyl -2,6-diphenyl-imidazo [1, 2-20 a] pyrazine: ÉMÉ ^ A solution of 2- [1 (S) - (1, 1-dimethylethoxy) carbonylamino} -2- (3-indolyl) ethyl] -1- (benzoylmethyl) -4-phenyl-1H-imidazole (prepared as previously described) (100 mg) in a mixture of 10% TFA in DCM (1.3 mL) was stirred for about 3 hours at about 20 ° C and concentrated under reduced pressure to produce the expected dihydroimidazo-pyrazine (yield = 95%). LC / MS: Calculated MW = 402.19, m / z = 403.2 (M + H).

Examples 12309-12532 The following compounds were prepared in a manner analogous to the procedure described for Example 12308, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to methods known to those skilled in the art. technical or as permitted by the teachings in the present. Each combination of R5 and R7, shown below, were or can be synthesized, therefore, the number of examples is calculated by multiplying (R5 (7 substituents) (R7 (32 substituents)) = 224.

R7 IMIDAZO- PIRAZINAS General Procedure: The intermediate compound (b) is treated with an acid solution preferably TFA in DCM at 20-30 ° C for 1-4 hours. The mixture is then concentrated under reduced pressure to give the compound (c) that is oxidized to the fully flavored imidazopyrazine., corresponding either to keeping it in methanol solution or DMSO for 5 hours - 3 days at about 20 ° C or using an oxidizing reagent such as manganese dioxide in a protic or aprotic solvent such as MeOH, toluene or chloroform at 20- 70 ° C for 2-10 hours or chromic acid supported or not in a resin in a protic solvent such as methanol at 40-70 ° C for 3-15 hours.

Example 12533 2,6-Diphenyl-imidazo [1,2-a] pyrazine-8-butanamine: A solution of 2- [1,5-bis. { (1, 1-dimethylethoxy] carbonylamino.} Pentyl] -4-phenyl-1H-imidazole (50 mg) in a mixture of 10% TFA / DCM (700 mL) at about 20 ° C for about 3 hours and then concentrated under reduced pressure to produce the dihydro-imidazo-pyrazine intermediate as its trifloroacetate salt.This salt was dissolved in MeOH (1 mL) and manganese dioxide (30 mg) was added after about 3 hours of stirring. at about 20 ° C, the mixture was filtered on a CELITE® pad and the filtrate was concentrated under reduced pressure to yield the fully flavored imidazo-pyrazine (68% yield). NMR (1H, 400 MHz, CD30D): 8.75-7.34 (m, 12H, arom.H), 3.32 (m, 4H, CH2), 2.10 (m, 2H, CH2), 1.90 (m, 2H, CH2). LC / MS: calculated MW = 342.4, m /z=343.2 (M + H).

Examples 12534-13773 The following compounds were prepared in a manner analogous to the procedure described for Example 12533, using the appropriate starting materials, which can be obtained from commercial sources or are synthesized according to methods known to those skilled in the art. in the art or as permitted by the teachings herein. Each combination of R3 and R7, shown below, were or can be synthesized, therefore, the number of examples is calculated by multiplying (R ~ (5 substituents)) (R5 (8 substituents)) (R7 (31 substituents)) = 1240.

R3 - mo mo.

"NH N- i R7 TETRAHIDRO-IMIDAZO-PIRAZINAS ^^ General Procedure: The intermediate compound ' (d) it is treated with an acid solution, preferably TFA er. DCM at 20-30 ° C for 1-4 hours. The mixture is then concentrated under reduced pressure to give the intermediate dihydro-imidazopyrazine compound (e). The reduction of (e) the corresponding tetrahydro-imidazopyrazine is achieved by catalytic hydrogenation or by using any reducing reagent such as NaBH (which can be supported on a resin), NaBH (0Ac) 3, NaBH3CN in a protic solvent such as MeOH at pH maintained weakly acidic (approximately pH 5) by the addition of acetic acid or TFA.

Example 13774 6-ethyl-5,6,7,8-tetrahydro-2-phenyl-8- (S) -phenylmethyl-imidazo [1,2-a] pyrazine: 2- [1 (S) -. { 1, 1-dimethylethoxy) carbonylamino} -2-phenylethyl] -1- (2-oxo-butyl) -4-phenyl-1H-imidazole (60 mg) in a mixture of 10% TFA in DCM was stirred at approximately ° C for about 3 hours and then concentrated under reduced pressure. The resulting intermediate dihydro-imidazo-pyrazine was dissolved in methanol and resin borohydride (AMBERLITE® IRA 400, Aldrich, 2.5 mmol of BH4 / g, 4 equivalents) was added. The pH was maintained at approximately 5 by the addition of drops of TFA. After about 2 hours of stirring at about 20 ° C, the mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (ethyl acetate / heptane 7: 3, Rf = 0.30). Tetrahydro-imidazo-pyrazine was obtained as an individual diastereomer in 86% yield (38 mg). NMR (XH, 400 MHz, CDCl 3) d: 7.80-7.10 (m, 11H, arom.H), 4.28 (dd, 1H, 3J = 10 Hz, 3J = 3Hz, H8), 3.95 (dd, 1H, 2J = 11.5 Hz, 3J = 3.6 Hz), 3.85 (dd, 1H, 2J = 13.6 Hz, 3J = 3.0 Hz), 3.60 (t, 1H, 2J = 3J = 11.5 Hz), 3.85 (dd, 1H, 2J = 13.6 Hz , 3J = 10 Hz), 2.98 (m, 2H), 1.85 (s, 1H, NH), 1.55 (m, 2H, CH2), 0.95 (t, 3H, CH3). NMR (13C, 100 MHz, CDC13): 146.3, 140.9, 138.0, 134.4, 129.4, 128.6, 128.5, 126.6, 126.5, 124.8, 113.8, 55.9, 54.4, 50.2, 40.0, 26.6, 10.0. LC / MS: Calculated MW = 317.43, m / z = 318.20 (M + H).

Example 13775 The following compound was prepared in a manner analogous to the procedure described for Example 13774, using the appropriate starting materials, which can be used. obtained from commercial sources or are synthesized according to methods known to those skilled in the art or as allowed by the teachings herein.

TETRAHIDRO-IMIDAZO-PIRAZINAS N-SUBSTITUIDAS (0 (3) General Procedure: A compound of the Formula (f) can react with isocyanates, isothiocyanates, N-succinimidyl-carbamates, acyl chlorides or activated carboxylic acids in an aprotic solvent at 20-70 ° C for 2-18 hours. The resulting derivative can be isolated by evaporation of the mixture followed by flash chromatography on silica gel or by addition to the mixture of a polymer-supported nucleophile such as aminomethyl- or thiomethyl-polystyrene resin followed by filtration.

Example 13776 5,6,7,8-tetrahydro-7- (methoxymethylcarbonyl) -2,6-diphenyl -8 (S) -phenylmethyl-imidazo [1,2-a] pyrazine To a solution of 5, 6, 7, 8-tetrahydro-2,6-diphenyl-8 (S) -phenylmethyl-imidazo [1,2-a] pyrazine (29 mg) in chloroform were successively added in a morpholine-methyl-polystyrene resin. (Novabiochem, loading = 3.51 mmol / g, 50 mg, 2 equivalents) and methoxyacetyl chloride (10 mL, 1.3 equivalents). After about 3 hours of stirring at about 20 ° C, chloroform is added to the mixture followed by aminomethylpolystyrene resin (Novabiochem, loading = 1.2 mmol / g, 132 mg, 2 equivalents). The reaction mixture is stirred for another 2 hours and then filtered. The filtrate was concentrated under reduced pressure to give 23 mg of the title compound (yield = 68%). NMR (^ ?, 100 MHz, CDC13) d: 7.9-7.0 (m, 16H, arom.H), 6.6 (m, 1H, H8), . 3 (m, 1H, H6), 4.6 (dd, 1H, 2J = 13 Hz, H5), 4.35 (dd, 1H, 2J = 13 Hz, 3J = 5 Hz, H5 '), 3.7-2.9 (m, 5H , CH2Ph, OCH3). The following tables of the compounds illustrate some of the compounds of the present invention that were synthesized and provide the HPLC retention time (denoted Rt or Tr) in minutes and the results of mass spectra of each compound. The mass spectra were acquired in an individual quadrupole electroroad mass spectrometer (Micromass, platform model), resolution 0.8 Da. A monthly calibration, between 80 and 1000 Da, is carried out with sodium iodide solution and rubidium isopropanol / water (1/1 vol). HPLC retention times were acquired in an HPLC system: HP1100 (Hewlett-Packard) equipped with a photodiode array UV detector. The HPLC conditions are as follows and the conditions used for each of the following tables of the compounds are noted below; the wavelength of the UV detector is indicated in parentheses after the formula number.

Condition A: Solvent: A: Water + 0.4% formic acid B: Acetonitrile + 0.4% formic acid Flow rate: 1 ml / min Injection volume: 20 μL Column: Kromasil ODS 5 μm 150 * 4.6 mm id. Temperature: 40 ° C.

Condition A2: Solvent: A: Water + 0.4% formic acid B: Acetonitrile + 0.4% formic acid Flow rate: 1 ml / min Injection volume: 20 μL Column: Kromasil ODS 5 μm 150 * 4.6 mm id. Temperature: 40 ° C.

Condition A3: Solvent: A: Water + 0.4% formic acid B: Acetonitrile + 0.4% formic acid Flow rate: 1 ml / min Injection volume: 20 μL Column: Kromasil ODS 5 μm 150 * 4.6 mm id. Temperature: 40 ° C.

Condition A4: Solvent: A: Water + 0.4% formic acid B: Acetonitrile + 0.4% formic acid Flow rate: 1 ml / min Injection volume: 20 μL Column: Kromasil ODS 5 μm 150 * 4.6 mm id. Temperature: 40 ° C.

Condition A5: Solvent: A: Water + 0.4% formic acid B: Acetonitrile + 0.4% formic acid Flow rate: 1 ml / min Injection volume: 20 μL Column: Kromasil ODS 5 μm 150 * 4.6 mm id. Temperature: 40 ° C.

Condition B: Solvent: A: Water + 0.02% trifluoroacetic acid B: Acetonitrile Flow rate: 1.1 ml / min Injection volume: 5 μL Column: Kromasil ODS 3 μm 33 * 4.6 mm id. Temperature: 40 ° C.

Condition C: Solvent: A: Water + 0.02% trifluoroacetic acid B: Acetonitrile Flow rate: 1.1 ml / min Injection volume: 5 μL Column: Kromasil ODS 3 μm 33 * 4.6 mm id. Temperature: 40 ° C.

Condition D: Solvent: A: Water + 0.04% trifluoroacetic acid B: Acetonitrile Flow rate: 1.1 ml / min Injection volume: 5 μL Column: Uptisphere ODS 3 μm 33 * 4.6 mm id. Temperature: 40 ° C.

Condition E: Solvent: A: Water + 0.4% trifluoroacetic acid B: Acetonitrile Flow rate: 1.1 ml / min Injection volume: 5 μL Column: Uptisphere ODS 3 μm 33 * 4.6 mm id.

Temperature: 40 ° C.

In the following description, the formula numbers are indicated in bold and the wavelengths are in parentheses. > Method A = Used for tables of the compounds of the formulas: 17 (250), 18 (250) and 57 (220) > Method A4 = Used for tables of the compounds of the formulas: 58 (210). > Method B = Used for tables of the compounds of the formulas: 7 (220), 8 (220), 9 (220), 10 (220), 11 (220), 12 (250), 19, (220), 20 (260), 21 (250), 25 (240), 26 (220), 27 (220), 28 (220), 29 (220), 37 (220), 38 (220), 39 (220), 40 (240), 44 (220), 45 (220), 46 (220), 47 (220), 48 (220), 49 (250), 55 (260), and 56 (220). > Method C = Used for tables of the compounds of the formulas: 1 (220), 2 (220), 3 (220), 4 (260), 5 (220), 6 (220), 13 (220), 14 ( 220), 16 (260), 23 (250), 24 (250), 30 (220), 31 (254), 32 (250), 33 (250), 34 (250), 35 (250) and 36 ( 254) Method D = Used for tables of the compounds of the formulas: 15 (220), 51 (220), 52 (220), 53 (220) and 54 (220) > Method E = Used for tables of the compounds of the Formulas: 22 (250), 41 (220), 42 (250), 43 (220) and 50 (250). 3 1 FORMULA 19 ANALYSIS • = [M + TFA-H] - R1 R2 Tr [M + H] + 80 A 5.3 335.3"^ twenty-one 2 6 FORMULA 32 ANALYSIS R1 Tr [M + H] + r £ j 64 5272 N02 210 FORMULA 40 ANALYSIS R1 Tr (M * H] + 36 336.4 49 420.3"^ N ^ CI X. 45 3864 3. 5 336.4 3. 8 336.4 49 432.3 31 & amp; amp; ..- & .. >

Claims (43)

1. CLAIMS: 1. A compound of the formula (I) (I) racemic-diastereomeric mixtures and optical isomers of the compounds of Formula (I), pharmaceutically acceptable salts and prodrugs thereof or a pharmaceutically acceptable salt thereof, wherein: represents an optional bond; R1 is H, - (CH2) mC (0) - (CH2) m -Z1, - (CH2) m -Z1, - (CH2) m-0-Z1 or - (C0-C6) alkyl-C (O) -NH- (CH2) m-Z3, Z1 is an optionally substituted portion selected from the group consisting of alkyl of 1 to 12 carbon atoms, benzo [b] thiophene, phenyl, naphthyl, benzo [b] furanyl, thiophene, isoxazolyl, indolyl, R2 is H or alkyl of 1 to 6 carbon atoms; "GaSs ** 'jgggg?? R1 and R2 are taken together with the nitrogen atoms to which they are attached to form a compound of Formula (Ia), (Ib), or (le), R3 is - (CH2) m-E- (CH2) m-Z2; E is O, S, -C (0) -, -C (0) -0-, -NH-C (O) -0- or a bond; Z2 is H, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -Ci2) alkylamino, alkylguanidino of 1 to 12 carbon atoms or a portion optionally substituted group selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; R4 is H or - (CHaJm-A1; A1 is -C (= Y) -N (X? X2), -C (= Y) -X2, -C (= NH) -X2 or X2, and is O or S; X1 is H, alkyl of 1 to 12 carbon atoms, - (CH2) m-NH- (C6-6) alkyl, - (CH2) mN-di- (Cx-C6) alkyl or (CH2) m -aryl, X2 is - (CH2) m-Y1-X3 or optionally substituted alkyl of 1 to 12 carbon atoms; Y1 is O, S, NH, C = 0, alkenyl of 2 to 12 carbon atoms having one or more double bonds, -NH-CO-, -CONH-, -NH-CO-0- (CH2) m- , C = C-, S02 or a link; X3 is H, an optionally substituted portion selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -C? 2) alkylamino, -CH-di- (C? -C? 2) alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl , indolyl, morpholino, benzo [b] furanyl, quinolinyl, isoquinolinyl, - (CH2) m-phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl, or X1 and X2 are taken together with the nitrogen to which they are bound to form an optionally substituted portion selected from the group consisting of thiazolyl is CH-X * 1 N-X "-C (X4X4), O or S; X4 for each occurrence is independently - (CH2) m-Y3-X5; Y3 is -C (O) -, -C (0) 0- or a bond; X5 is hydroxy, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (Ci-C? 2) alkylamino, or an optionally substituted portion selected from the group consists of aryl, aryl (C? -C4) alkyl, furanyl, pyridinyl, indolyl, -CH (phenyl) 2, R5 is alkyl of 1 to 12 carbon atoms, (C0-C6) alkyl-C (O) -O-Z5, (C0-C6) alkyl-C (0) -NH- (CH2) m-Z3 or arylc optionally replaced; Z3 for each occurrence is independently amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C1-C12) alkylamino, -NH-C (O) -O- (CH2) m-phenyl -NH-C (O) -O- (CH2) m- (Ci-C6) alkyl or an optionally substituted portion selected from the group consisting of 'imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl and thiophene; Rs is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or - (CH2) m-Z4; Z is an optionally substituted portion selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo [b] furan, benzo [b] thiophene, isoxazolyl, Z5 is H, alkyl of 1 to 12 carbon atoms, (CH2) m-aryl; wherein an optionally substituted portion is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF3, CN, N3, N02, OH, S02NH2, -OCF3, alkoxy from 1 to 12 carbon atoms, - (CH2) m-phenyl- (X6) n, -S-phenyl- (X6) n, -S- (C1-C12) alkyl, -O- (CH2) m-phenyl - (X6) n - (CH2) mC (0) -O- (d-C6) alkyl, - (CH2) mC (O) - (d-C6) alkyl, -O- (CH2) m-NH2, - O- (CH2) m-NH- (d-C6) alkyl, -0- (CH2) mN-di - ((C? -C6) alkyl) and - (C0-C12) alkyl- (X6) n; X6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, N02, N3, CN, OH, -CF3, -0CF3, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, - (CH2) m-NH2, - (CH2) m-NH- (C6-6) alkyl, - (CH2) mN-di- ((C6-6) alkyl) and - ( CH2) m-phenyl; m for each occurrence is independently 0 or an integer from 1 to 6; and n for each occurrence is independently an integer from 1 to 5; with the proviso that: (a) when R5 is alkyl of 1 to 12 carbon atoms or -C (0) -0-Z5 and Z5 is alkyl of 1 to 12 carbon atoms or optionally substituted aryl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or Z4 and Z4 is thiophene or optionally substituted phenyl, then R3 is not -C (O) -O- (CH2) mZ wherein m is 0 and Z is H or alkyl of 1 to 12 carbon atoms or where m is 1 or 6 and Z is H; (b) when R5 is alkyl of 1 to 12 carbon atoms or optionally substituted phenyl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms and R3 is -O- (CH2) -Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; and (c) when R5 is H or alkyl of 1 to 12 carbon atoms; R6 is alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms; and R3 is -O-Z2 or -S-Z2, BiHALMILMÉail then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl.
2. 2. A compound according to claim 1, wherein R1 is H; R2 is H; R3 is -CH2-phenyl; R4 is - (CH ^ O-A1 where m in the definition of R4 is 0, R5 is phenyl, R6 is H, where A1 is -C (= Y) -N (X ^ í); Y is O; X1 is H or methyl, X2 is - (CH2) m-? X? 3; m in the definition of X2 is 0, 1, 2 or 3; Y1 is a bond or O; and X3 is N-methylpyrrolidin-2-yl, diethylamino, pyridinyl, thiophene, imidazolyl, diethoxymethyl, 1-benzyl-piperidin-4-yl, optionally substituted phenyl or
3. 3. A compound according to claim 1, wherein R1 is H; R2 is H; R3 is -CH2-phenyl; R4 is - (CHOm-A1 where m in the definition of R4 is 0, R5 is phenyl, R6 is H, where A1 is -C (= Y) -N (X ^ í2), Y is O, X1 is benzyl and X2 is 2-hydroxyethyl; or X1 and X2 are taken together with the nitrogen atom to which they are bound to form where Y2 is C-X4 or N-X4; X4 is - (CH2) m-Y3-X5 where m in the definition of X4 is 0 or 1, and X5 is selected from the group consisting of furanyl, benzyl, phenyl, amino,
4. 4. A compound according to claim 1, wherein R1 is H; R2 is H; R3 is -CH2-phenyl; R4 is - (CT ^ O-A1 where m in the definition of R4 is 0, R5 is phenyl, R6 is H, where A1 is -C (= Y) -X2, Y is O, X2 is - (CH2) m-Y1-X3, where m in the definition of X2 is 0, 1 or 2, Y1 is O, -NH-CO-, -CO-NH-, -NH-C0-0-CH2-, S02 or a bond and X3 is methyl, furanyl, pentyl, phenyl, indolyl, p-N02-phenyl, naphthyl, fluorenyl, -CH (phenyl) 2, benzothiazolyl, fatalamidyl, N, N-dimethylamino.
5. 5. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CHsO- 1 where m in the definition of R4 is 0, R5 is phenyl or t-Bu, R6 is H, A1 is -C (= Y) -N (X- * X2), Y is O or S; X1 is H; X2 is - (CH2) m-? X? 3; m in the definition of X2 is 0, 1 or 2; Y1 is a bond; and X3 is phenyl, o-Cl-phenyl, m- Cl-phenyl, p-phenyloxy-phenyl, 2,6-di-isopropylphenyl, m-CF 3 -phenyl, p-ethoxycarbonyl-phenyl, 2,4-difluorophenyl, m-N 0 2 -phenyl, p-benzyloxyphenyl, o-isopropylphenyl, n-hexyl, 4-morpholino, naphthyl or
6. 6. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CHsO-A1 where m in the definition of R4 is 0; R5 is phenyl or t-Bu; RÉ 'is H; where A1 is -C (= Y) -X2; Y is O; X2 is - (CH2) m-Y1-X3; where m in the definition of X2 is 0, 1, or 2; Y1 is 0, -CO-NH-, -NH-C0-0-CH2- or a bond; and X3 is methyl, 3-pentyl, phenyl, p-N02-phenyl, phthalamidyl, N, N-dimethylamino, p-aminophenyl, fluorenyl or
7. 7. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CHaO-A1 where m in the definition of R4 is 0, R5 is phenyl or t-Bu, R6 is H, where A1 is -C (= Y) -N (X ^ 2), Y is O; X1 is hydrogen, X2 is - (CH2) m-? X? 3, where m in the definition of X2 is 0, 1, 2 or 3, Y1 is 0 or a bond, and X3 is cyclopentyl, 4-OH-butyl , N, N-diethylamino, N-methyl-pyrrolidin-3-yl, -CH (ethoxy) 2, phenyl, p-S02NH2-phenyl, p-OH-phenyl, o-CF3-phenyl, p-Cl-phenyl, -CH (phenyl) 2,
8. 8. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is -CH2-indol-3-yl; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl or t-Bu; R6 is H; where A1 is -C (= Y) -X2; And it is 0; X2 is - (CH2) m-Y1-X3; where m in the definition of X2 is 0, 1, 2 or 3; Y1 is -NH-CO, -C = C-, -C = C- or a bond; and X3 is t-butyl, l-methylcarbonyl-piperidin-4-yl, phenyl, p-Cl-phenyl, m-CF3-phenyl, 4-nitro-naphthyl, p-methoxy-phenyl, m- (phenylethyl) -phenyl , indol-3-yl or p-aminophenyl.
9. 9. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is -CH2-indol-3-yl, - (CH2) 4-NH-C0-0-t-Bu or - (CH2) -NH2; R4 is - (CH ^ m- 1 where m in the definition of R4 is 0; R5 is phenyl, o-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or pN, N-diethylamino-phenyl; R6 is H where A1 is -C (= Y) -N (X ^ 2); Y is O; X1 is H; X2 is - (CH2) m-Y1-X3; where m in the definition of X2 is 0; Y1 is a link; and X3 is o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-nitro-phenyl, m-nitro-phenyl , p-nitro-phenyl, o-CF3-f nyl, m-CF3-phenyl, p-CF3-phenyl, pF-phenyl, 2,4-di-F-phenyl, 2,5-di-F-phenyl, 2, 5-di-methoxy-phenyl, m-OMe-phenyl, p-OMe-phenyl, 2-CF3-4-Cl-phenyl or 3-nitro-4-F-phenyl.
10. 10. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is -CH2-indole-3-yl, (CH2) 4-NH -CO-O-t-Bu or - (CH2) 4-NH; R4 is - (CT ^ O-A1 where m in the definition of R4 is 0; R5 is phenyl, o-methoxyphenyl, p-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or pN, N-diethylamino-phenyl R6 is H, where A1 is -C (= Y) -X2, Y is O, X2 is - (CH2) m-? X? 3, where m in the definition of X2 is 1, Y1 is a bond, and X3 is phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl phenyl, o-nitro-phenyl, m-nitro-phenyl , p-nitro-phenyl, o-CF3-phenyl, m-CF3-phenyl, p-CF3-phenyl, oF-phenyl, mF-phenyl, pF-phenyl, N, N-di-methylamino-phenyl, o-OMe phenyl, m-OMe-phenyl, p-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl or , 4-di-F-phenyl
11. 11. A compound according to claim 9 wherein R5 is phenyl and R3 is - (CH2) -indol-3-yl that the stereochemistry at the carbon to which R3 is attached is in the configuration R.
12. 12. A compound according to claim 10 wherein R5 is phenyl and R3 is - (CH2) -indol-3-yl that the stereochemistry at the carbon to which R3 is attached is e. n the R configuration.
13. 13. A compound according to claim 10 wherein R5 is o-OMe-phenyl and R3 is - (CH2) -indol-3-yl that the stereochemistry at the carbon to which R3 is attached is in the configuration R.
14. 14. A compound according to claim 10 wherein R5 is o-OMe-phenyl and R3 is - (CH2) -indol-3-yl that the stereochemistry at the carbon to which R3 binds is in the S-configuration.
15. A compound according to claim 1 wherein 'R1 is H; R2 is H; R3 is - (CH2) 4-NH-CO-0-t-Bu or - (CH2) 4-NH2; R is - (CH ^ m-A1 where m in the definition of R4 is 0, R5 is phenyl, R6 is H, where A1 is -C (= Y) -X2, Y is O, X2 is - (CH2) m-Y1-X3, where m in the definition of X2 is 0, 1 0 2, Y1 is S, S02 or a bond, and X3 is phenyl, 3,4-di-Cl-phenyl, 3, 4, 5- tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl, 2,4-di-F-phenyl, 2-furanyl, 2-pyridinyl, 3-pyridinyl, naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 8-quinolinyl, 1-isoquinolinyl, 2-thiophene or 2- pyrimidinyl.
16. 16. A compound according to claim 1 wherein 'R1 is H; R2 is H; R3 is - (CH2) 4-NH-C0-0-t-Bu or - (CH2) 4-NH2; R ** is - (CH2) m-A1, where m in the definition of R4 is 0; R5 is phenyl; R6 is H; where A1 is -C (= Y) -X2; And it is 0; X2 is - (CH2) m-Y ^ X3; where m in the definition of X2 is 0, 1, 2 or 3; Y1 is a link; and X3 is 5-indolyl, 3-indolyl, 4-indolyl, 2-indolyl, 5-OMe-indol-3-yl, 5-OMe-indol-2-yl, 5-OH-indol-2-yl, 5-0H-indol-3-yl, 5-Br-indol-3-yl, 2-Me-indol-3-yl, 2-benzothiophene, 3-benzothiophene, or 2 -benzofuran.
17. 17. A compound according to claim 1 wherein 'R1 is H; R2 is H; R3 is - (CH2) m-indol-3-yl, - (CH2) 4-NH-CO-0-t-Bu or - (CH2) 4-NH2; R4 is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl, o-OMe-phenyl or p-OME-phenyl; R6 is H; where A1 is X2; X2 is - (CH2) m-? X? 3; where m in the definition of X2 is 1, 2 or 3; Y1 is S, O or a link; and X3 is phenyl, O-OH-phenyl, p-OH-phenyl, oF-phenyl, mF-fyl, pF-phenyl, o-CF3-phenyl, o-OMe-phenyl, m-OMe-phenyl, o-nitro -phenyl, p-nitro-phenyl, 3, 4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, 2-thiophene, 3, 4, 5-tri- OMe-phenyl, p- N, N-dimethylamino-phenyl, p-OCF3-phenyl, p- (3- (N, N-dimethylamino) propoxy) phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, methyl, n-butyl, n-pentyl, n-hexyl, 3, 3-dimethyl-butyl, benzyl, cyclohexyl or p-t-Bu-phenyl.
18. 18. A compound according to claim 1 wherein R1 is H; R2 is H; R3 is - (CH2) 4-NH-CO-0-t-Bu or - (CH2) 4-NH2; R4 • -TO- "-,-" , . is - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl; R6 is H; where A1 is X2; X2 is - (CH2) m-? X? 3; where m in the definition of X2 is 1, 2 or 3; Y1 is 0 or a link; and X3 is phenyl, o-OH-phenyl, p-OH-phenyl, oF-phenyl, nF-phenyl, pF-phenyl, o-CF3-phenyl, o-OMe-phenyl, m-OMe-phenyl, p-OMe -phenyl, p-nitro-phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, 0-Br-phenyl, n-Br-phenyl, p-Br phenyl, p-phenyl-phenyl, 2-thiophene, 3,4,5-tri-OMe-phenyl, pN, N-dimethylamino-phenyl, p-benzyloxy-phenyl, p-0CF3-phenyl, p- (3- (N, N-dimethylamino) propoxy) phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, 3 -indolyl, 6-methoxycarbonyl-indol-3-yl, l-methyl-indol-3-yl, 2-methyl-indol-3-yl, methyl, n-butyl, n-pentyl, n-hexyl, 3, 3 -dimethyl-butyl, benzyl, cyclohexyl or pt-Bu-phenyl.
19. 19. A compound according to claim 1 wherein 'R1 is (CHaOCO-Z1; R2 is H; R3 is - (CH2) 4-NH-CO-0-t-Bu, - (CH2) 4-NH-CO- 0-benzyl, - (CH 2) -indol-3-yl, R 4 is - (CH 2) mA where m in the definition of R 4 is 0, R 5 is phenyl, R 6 is H, where Z 1 is ethyl, phenyl, p-OMe phenyl, p-phenyl-phenyl, p-Cl-phenyl, p-Br-phenyl, p-N3-phenyl, pF-phenyl, m-nitro-phenyl, p-nitro-phenyl, p-CN-phenyl, 2,5-di -OMe-phenyl, 3,4-di-Cl-phenyl, N, N-dimethylamino-phenyl, 3-methyl-4-Cl-phenyl or naphthyl; A1 is -C (= Y) -X2; Y is 0; X2 is - (CH2) m-? X? 3; where m in the definition of X2 is 0; Y1 O; and X3 is t -Bu
20. 20. A compound according to claim 1 wherein R1 is - (CH2) -CO- (CHaO-Z1 where m in the definition of R1 is 0, 1 or 2; R2 is H; R3 is -CH2-indole -3-yl, or - (CH2) 4-NH-CO-0-t-Bu; R4 is H or - (CH2) m-A1 where m in the definition of R4 is 0; R5 is phenyl, o-OMe-phenyl, p-nitro-phenyl, p-Br-phenyl, t-Bu, -CH (CH3) 2-CO-NH- (CH2) 2 -CO-0-t-Bu, -CH (CH3) 2-C0-NH- (CH2) 3 -4-morph olino, -CH (CH3) 2-CO-NH- (CH2) 2-pyridin-4-yl or -CH (CH 3) 2 -CO-NH- (CH 2) 2 -N, N-diethylamino; R6 is H; wherein Z1 is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, pF-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p -N3-phenyl, p-phenyl-phenyl, 3- Me-4-Cl-phenyl, pN, N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3 , 4-di-F-phenyl, p-OCF3-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-Nitro-4-Cl-phenyl, 3-Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazole-5- ilo, 3- (2,4-di-Cl-phenyl) -isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl, A1 is -C (= Y) -X2 Y is O; X is - (CH2) m-Y -X; where m in the definition of X2 is 0; Y1 is O; and X3 is t-Bu.
21. 21. A compound according to claim 1 wherein R1 and R2 are taken together to form a compound of the Formula (Ib) or (le); R3 is -CH2-indol-3-yl, - (CH2) -phenyl, - (CH2) 4-NH-CO-0-benzyl or - (CH2) 4-NH2; R5 is phenyl, o-OMe-phenyl, p-OMe-phenyl, p-Br-phenyl, p-nitro-phenyl, t-Bu or -CH (CH3) 2-CO-NH- (CH2) 2-NH2; Re is H; R7 is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, pF-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p- N3-phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, pN, N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3, 4-di-F-phenyl, p-OCF3-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, 3- Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3- (2,4-di-Cl) phenyl) -isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl,
22. 22. A compound of the formula (II) (ll) the racemic-diastereomeric mixtures and optical isomers of the compounds of the Formula (II), the pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salt of the drug, wherein it represents an optional bond; R1 is H, - (CH2) mC (0) - (CH2) m -Z1 (CH1? (CH2 -O-Z1 or - (C0-C6) alkyl-C (O) -NH- (CH2) m- Z3, Z1 is an optionally substituted moiety selected from the group consisting of alkyl of 1 to 12 carbon atoms, benzo [b] thiophene, phenyl, naphthyl, benzo [b] furanyl, thiophene, isoxazolyl, indolyl, . '*. «.., .. •. . R2 is H or alkyl of 1 to 6 carbon atoms; or R1 and R2 are taken together with the nitrogen atoms to which they are attached to form a compound of Formula (Ha), (Hb), or (He), R3 is - (CH2) m-E- (CH2) m-Z2; E is O, S, -C (O) -, -C (0) -0-, -NH-C (0) -0-, N (C? -C6) alkyl-C (0) -O- or a link; Z2 is H, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -C? 2) alkylamino, alkylguanidino of 1 to 12 carbon atoms or optionally substituted portion selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; A1 is -C (= Y) -N (X? X2), -C (= Y) -X2, -C (= NH) -X2 or X2, Y is O or S; X1 is H, alkyl of 1 to 12 carbon atoms, - (CH2) m-NH- (C? -C6) alkyl, - (CH2) mN-di- (C? -C6) alkyl or (CH2) m- aril; X2 is - (CH2) m-? X? 3 or optionally substituted alkyl of 1 to 12 carbon atoms; Y1 is O, S, NH, C = 0, alkenyl of 2 to 12 carbon atoms having one or more double bonds, -NH-CO-, -CONH-, -NH-CO-0- (CH2) m- , C = C-, S02 or a link; X3 is H, an optionally substituted portion selected from the group consisting of alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, alkylamino of 1 to 12 carbon atoms, N, N-di- (C? -C? 2) alkylamino, -CH-di- (C? -C? 2) alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl , indolyl, morpholino, benzo [b] furanyl, quinolinyl, isoquinolinyl, - (CH2) m-phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl, or X1 and X2 are taken together with the nitrogen to which they are bound to form an optionally substituted portion selected from the group consisting of thiazolyl Y ¿is CH-XX N-X ** -C ^ X * 3 O or S; X4 for each occurrence is independently H or - (CH2) m-Y3-X5; Y3 is -C (O) -, -C (0) * 0- or a bond; X5 is hydroxy, alkyl of 1 to 12 carbon atoms, amino, alkylamino of 1 to 12 carbon atoms, N, N-di- (C-C12) alkylamino, or an optionally substituted portion selected from the group consisting of aryl, aryl (C? -C4) alkyl, furanyl, pyridinyl, indolyl, piperidinyl, -CH (phenyl) 2, R5 is alkyl of 1 to 12 carbon atoms, (C0-C6) alkyl-C (O) -O-Z5, (C0-C3) alkyl-C (O) -NH- (CH2) m-Z3 or aryl optionally replaced; Z3 for each occurrence is independently amino, alkylamino of 1 to 12 carbon atoms, amino (C? -C12) -alkyl, cycloalkylamino of 5 to 7 carbon atoms, amino (C5-C7) cycloalkyl, N- (C? - C12) alkylamino, N, N-di- (C? -C? 2) alkylamino, -NH-C (O) -O- (CH2) m-phenyl -NH-C (O) -O- (CH2) m - (C? -C6) alkyl, -CH (phenyl) 2, (C5_C7) cycloalkyl. H2N- (C Cx-Cg) alkyl-C (O) -O- (C -C -C6) alkyl optionally substituted phenyl- (CH2) m-0-C (O) -NH- (C6-6) alkylC (O) -O- (C6C6) alkyl OR an optionally substituted portion selected from the group which consists of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl, phenyl, indolyl and thiophene, with the proviso that when m is 0 in the formula for R5 then Z3 is not -NH-C (O) -O- (CH2) m-phenyl or -NH-C (O) -O- (CH2) m- (C? -C6) alkyl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or - (CH2) m-Z4; Z4 is an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo [b] furan, benzo [b] thiophene, isoxazolyl, Z5 is H, alkyl of 1 to 12 carbon atoms, (CH2) m-aryl; wherein an optionally substituted portion is, optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF3, CN, N3, N02, OH, S02NH2, -OCF3, alkoxy of 1 to 12 carbon atoms, - (CH2) m-phenyl- (X6) n, -S-phenyl- (X6) n, -S- (C? -C? 2) alkyl, -O- (CH2 ) m-phenyl- (X6) n, - (CH2) mC (O) -0- (C? -C6) alkyl, - (CH2) mC (O) - (C? -C6) alkyl, -0- ( CH2) m-NH2, -O- (CH2) m-NH- (C? -C6) alkyl, -0- (CH2) mN-di- ((C? -C6) alkyl) and - (C0-C? 2) alkyl- (X6) a and (CH2) m-phenyl-X7; X6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, N02, N3, CN, OH, -CF3, -0CF3, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, - (CH2) m-NH2, - (CH2) m-NH- (C-C6) alkyl, - (CH2) mN-di- ((C? -C6) alkyl) and - (CH2) ) m-phenyl; X7 is -NH-C (= NH-H1) -X8, wherein X8 is thiophene, alkyl of 1 to 6 carbon atoms or phenyl; m for each occurrence is independently 0 or an integer from 1 to 6; and n for each occurrence is independently an integer from 1 to 5; with the proviso that: (a) when R5 is alkyl of 1 to 12 carbon atoms or -C (0) -0-Z5 and Z5 is alkyl of 1 to 12 carbon atoms or optionally substituted aryl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms or Z4 and Z4 is thiophene or optionally substituted phenyl, then R3 is not -C (O) -O- (CH2) mZ wherein m is 0 and Z is H or alkyl of 1 to 12 carbon atoms or er. where m is 1 to 6 and Z is H; (b) when R? is alkyl of 1 to 12 carbon atoms or optionally substituted phenyl; R6 is H or alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms and R3 is -0- (CH2) -Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; and (c) when R5 is H or alkyl of 1 to 12 carbon atoms; R6 is alkyl of 1 to 6 carbon atoms; R7 is alkyl of 1 to 12 carbon atoms; and R3 is -O-Z2 or -S-Z2, then Z2 is not an optionally substituted portion selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl.
23. 23. A compound according to claim 22 of the formula where -,. -aa-K. u¿Stf $ £ UUW * Ji. ** - Zó is -CH 2 -NH 2 (CH 2) 2 -NH 2, (CH 2) 3 -NH 2 X1 is - (CH2) 2-N (CH3) 2 and X2 is benzyl; or X1 and X2 are taken together with the nitrogen atom to which they are attached to form:
24. 24. A compound according to claim 22 of the formula: wherein Z3 is X1 is - (CH2) 2-N (CH3) 2 and X2 is benzyl; or X1 and X2 are taken together with the nitrogen atom to which they are bound to form
25. 25. A compound according to claim 22 of the formula: wherein X2 is p-chloro-phenyl, p-methoxy-phenyl, 2,4-difluoro-phenyl, or thienyl.
26. 26. A compound according to claim 22 of the formula: wherein X2 is p-chloro-phenyl, p-methoxy-phenyl, phenyl-thienyl.
27. 27. A compound according to claim 22 of the formula:
28. 28. A compound according to claim 22 of the formula:
29. 29. A compound according to claim 22 of the formula: where R ° is and R7 is m-nitro-f-enyl or 2-f-enyl-ethyl; or ilo or R3 is and R is 3,4-dichlorophenyl.
30. 30. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
31. 31. A method for producing an agonist effect of one or more somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to the subject.
32. 32. A method for producing an antagonistic effect of one or more somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to the subject.
33. 33. A method for joining one or more of the somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to the subject.
34. 34. A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pseudocistis and pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, diarrhea syndrome, AIDS related diarrhea, diarrhea associated with chemotherapy, scleroderma, irritable bowel syndrome, pancreatitis, small bowel obstruction, gastroensofágico reflux, duodenogastric reflux, Cushing's syndrome, gonadotropinoma, hyperparathyroidism, Graves' disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, caquexica by cancer, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to the subject.
35. 35. A method for treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, beginning phenomenon, Nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, drain (Dumping) syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, secreting tumors gastrointestinal hormone, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, bleeding spleens graft or gastrointestinal bleeding in a subject in need thereof comprising administering a compound according to claim 1 or pharmaceutically acceptable salt thereof to the subject.
36. 36. A method for inhibiting the proliferation of Helicobacter pylori in a subject in need thereof, comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to the subject.
37. 37. A pharmaceutical composition comprising a compound according to claim 22 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
38. 38. A method for producing an agonist effect of one or more somatostatin receptor subtypes in a subject in need thereof, comprising administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to the subject.
39. 39. A method for producing an antagonistic effect of 'one or more subtypes of somatostatin receptor in ur. subject in need thereof, which comprises administering the compound ur according to claim 22 or a pharmaceutically acceptable salt thereof to the subject.
40. 40. A method for joining one or more somatostatin receptor subtypes in a subject in need thereof, which comprises administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to the subject.
41. 41. A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pseudocistis and pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, diarrhea syndrome, AIDS related diarrhea, diarrhea associated with chemotherapy, scleroderma, irritable bowel syndrome, pancreatitis, small bowel obstruction, gastroensofágico reflux, duodenogastric reflux, Cushing's syndrome, gonadotropinoma, hyperparathyroidism, Graves' disease, neuropathy, diabetic, Paget's disease, polycystic ovary disease, cancer, caquexica for cancer, hypotension, postprandial hypotension, panic attacks, adenomas secreting GH or adenomas secreting TSH, in a subject in need thereof, which comprises administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to the subject.
42. 42. A method for treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, beginning phenomenon, Nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, drain (Dumping) syndrome, watery diarrhea syndrome, acute pancreatitis chronic c, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft spleens bleeding and gastrointestinal bleeding in a subject in need thereof comprising administering a compound according to -TO -. claim 22 or a pharmaceutically acceptable salt thereof to the subject.
43. 43. A method for inhibiting the proliferation of Helicobacter pylori in a subject in need thereof, comprising administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to the subject.